<PAPER><mode2 name='PMC3542580' hasDoc='yes' version='597'></mode2><article xml:lang='en' xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>BMC Med</journal-id><journal-id journal-id-type='iso-abbrev'>BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type='epub'>1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>3542580</article-id><article-id pub-id-type='publisher-id'>1741-7015-10-105</article-id><article-id pub-id-type='pmid'>22989295</article-id><article-id pub-id-type='doi'>10.1186/1741-7015-10-105</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis</s></article-title></title-group><contrib-group><contrib contrib-type='author' id='A1'><name><surname>Liu</surname><given-names>Rui</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>liurui@imm.ac.cn</email></contrib><contrib contrib-type='author' id='A2'><name><surname>Wu</surname><given-names>Cai-xia</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I3' ref-type='aff'>3</xref><email>sdyx91@126.com</email></contrib><contrib contrib-type='author' id='A3'><name><surname>Zhou</surname><given-names>Dan</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>zhoudan@imm.ac.cn</email></contrib><contrib contrib-type='author' id='A4'><name><surname>Yang</surname><given-names>Fan</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>liurui0420@sohu.com</email></contrib><contrib contrib-type='author' id='A5'><name><surname>Tian</surname><given-names>Shuo</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>zhaole_bjciq@163.com</email></contrib><contrib contrib-type='author' id='A6'><name><surname>Zhang</surname><given-names>Li</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>zhangli@imm.ac.cn</email></contrib><contrib contrib-type='author' id='A7'><name><surname>Zhang</surname><given-names>Tian-tai</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>ttzhang@imm.ac.cn</email></contrib><contrib contrib-type='author' corresp='yes' id='A8'><name><surname>Du</surname><given-names>Guan-hua</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>bessie0420@163.com</email></contrib></contrib-group><aff id='I1'><label>1</label>National Center of Pharmacological Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100050, P R China</aff><aff id='I2'><label>2</label>State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P R China</aff><aff id='I3'><label>3</label>Shenyang Pharmaceutical University, Shenyang, 110016, P R China</aff><pub-date pub-type='collection'><year>2012</year></pub-date><pub-date pub-type='epub'><day>18</day><month>9</month><year>2012</year></pub-date><volume>10</volume><fpage>105</fpage><lpage>105</lpage><history><date date-type='received'><day>13</day><month>7</month><year>2012</year></date><date date-type='accepted'><day>18</day><month>9</month><year>2012</year></date></history><permissions><copyright-statement>Copyright ©2012 Liu et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Liu et al; licensee BioMed Central Ltd.</copyright-holder><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by/2.0'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/2.0'>http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href='http://www.biomedcentral.com/1741-7015/10/105'></self-uri><abstract><sec><title>Background</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>It is known that amyloid-β peptide (Aβ) plays a pivotal role in the pathogenesis of Alzheimer's disease (AD).</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Interaction between Aβ and the receptor for advanced glycation end products (RAGE) has been implicated in neuronal degeneration associated with this disease.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Pinocembrin, a flavonoid abundant in propolis, has been reported to possess numerous biological activities beneficial to health.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Our previous studies have demonstrated that pinocembrin has neuroprotective effects on ischemic and vascular dementia in animal models.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It has been approved by the State Food and Drug Administration of China for clinical use in stroke patients.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Against this background, we investigated the effects of pinocembrin on cognitive function and neuronal protection against Aβ-induced toxicity and explored its potential mechanism.</s></p></sec><sec><title>Methods</title><p><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Mice received an intracerebroventricular fusion of Aβ<sub>25-35</sub>.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Pinocembrin was administrated orally at 20 mg/kg/day and 40 mg/kg/day for 8 days.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Behavioral performance, cerebral cortex neuropil ultrastructure, neuronal degeneration and RAGE expression were assessed.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Further, a RAGE-overexpressing cell model and an AD cell model were used for investigating the mechanisms of pinocembrin.</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The mechanisms underlying the efficacy of pinocembrin were conducted on target action, mitochondrial function and potential signal transduction using fluorescence-based multiparametric technologies on a high-content analysis platform.</s></p></sec><sec><title>Results</title><p><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Our results showed that oral administration of pinocembrin improved cognitive function, preserved the ultrastructural neuropil and decreased neurodegeneration of the cerebral cortex in Aβ<sub>25-35</sub>-treated mice.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Pinocembrin did not have a significant effect on inhibiting Aβ<sub>1-42 </sub>production and scavenging intracellular reactive oxygen species (ROS).</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, pinocembrin significantly inhibited the upregulation of RAGE transcripts and protein expression both <italic>in vivo </italic>and <italic>in vitro</italic>, and also markedly depressed the activation of p38 mitogen-activated protein kinase (MAPK)-MAPKAP kinase-2 (MK2)-heat shock protein 27 (HSP27) and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK)-c-Jun pathways and the downstream nuclear factor κB (NFκB) inflammatory response subsequent to Aβ-RAGE interaction.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In addition, pinocembrin significantly alleviated mitochondrial dysfunction through improving mitochondrial membrane potential and inhibiting mitochondrial oxidative stress, and regulated mitochondrion-mediated apoptosis by restoration of B cell lymphoma 2 (Bcl-2) and cytochrome <italic>c </italic>and inactivation of caspase 3 and caspase 9.</s></p></sec><sec><title>Conclusions</title><p><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Pinocembrin was shown to infer cognitive improvement and neuronal protection in AD models.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The mechanisms of action of the compound were illustrated on RAGE-dependent transduction inhibition and mitochondrion protection.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> It appears to be a promising candidate for the prevention and therapy of AD.</s></p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>amyloid-β peptide</kwd><kwd>apoptosis</kwd><kwd>pinocembrin</kwd><kwd>receptor for advanced glycation end products</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the presence of senile plaques, intracellular neurofibrillary tangles and neuronal loss [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Amyloid-β peptide (Aβ) is found in extracellular senile plaque cores and is recognized as one of the vital neuropathological hallmarks of AD.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Although the exact mechanism of Aβ-induced cell damage is unclear, multiple molecular pathways resulting in cell death are involved in vulnerable neuronal populations [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>].</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Surrounding the amyloid plaques, there is an apparent chronic progressive inflammatory response in neuronal cells [<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cytoplasmic blebbing, mitochondrial calcium dyshomeostasis, cytochrome <italic>c </italic>release, chromatin condensation, nuclear damage, and DNA fragmentation can also be activated locally following exposure to Aβ [<xref rid='B5' ref-type='bibr'>5</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Increased intracellular Aβ levels could further facilitate opening of the mitochondrial permeability transition pores [<xref rid='B6' ref-type='bibr'>6</xref>].</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This indicates that Aβ can directly disrupt mitochondrial function, reduce energy metabolism and contribute to the mitochondrion-dependent apoptosis.</s></p><p><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Aβ is a pleiotropic peptide and is capable of binding to the receptors at several different membrane locations [<xref rid='B7' ref-type='bibr'>7</xref>].</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The receptor for advanced glycation end products (RAGE), a multiligand receptor of the immunoglobulin superfamily of cell surface molecules [<xref rid='B8' ref-type='bibr'>8</xref>-<xref rid='B10' ref-type='bibr'>10</xref>], possesses a cell surface binding site for Aβ peptides [<xref rid='B7' ref-type='bibr'>7</xref>] and is expressed at higher levels when stimulated by excessive amounts of Aβ [<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> RAGE has been extensively studied for its role in migration and differentiation of neuronal cells during development, perturbation of neuronal cells by Aβ and for its role in the inflammatory response [<xref rid='B11' ref-type='bibr'>11</xref>,<xref rid='B13' ref-type='bibr'>13</xref>-<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The wild-type RAGE transgene targeted to neurons in the transgenic AD mouse model that expressed mutant human amyloid precursor protein (APP) has been shown to accelerate Aβ-mediated neuronal perturbation [<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the same way, administration of Aβ has been shown to be cerebrotoxic, and RAGE was also robustly expressed throughout the adult rat brain in neurons and glia in ischemic pathology [<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> As a consequence of Aβ-RAGE interaction, activation of p38 mitogen-activated protein kinases (p38MAPK), stress-activated protein kinase or c-Jun N-terminal kinase (SAPK/JNK), and nuclear factor κB (NFκB) signaling transduction was seen in synaptic failure of sporadic AD cybrids [<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Therefore, Aβ-RAGE is known to be a key mediator of neuronal damage in AD, as well as a contributor to stroke pathology through dependent upregulation of inflammatory cytokines and NFκB [<xref rid='B19' ref-type='bibr'>19</xref>].</s></p><p><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Pinocembrin (5,7-dihydroxyflavanone; Figure <xref rid='F1' ref-type='fig'>1A</xref>) is a natural flavonoid found at high concentration in propolis.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It has been extracted as a pure compound from propolis, and subsequently pinocembrin was synthesized and approved by the State Food and Drug Administration (SFDA) of China for stroke clinical trials in 2008.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This compound is well metabolized and can circulate in the body after oral administration [<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In particular, it is able to pass through the blood-brain barrier (BBB) in a passive transport process partly conducted by P-glycoprotein [<xref rid='B21' ref-type='bibr'>21</xref>].</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Our previous studies have showed that pinocembrin reduced glutamate-induced SH-SY5Y cell injury, protected primary cortical neurons against oxygen-glucose deprivation/reoxygenation injury [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B23' ref-type='bibr'>23</xref>], and reduced the area of cerebral infarct [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B24' ref-type='bibr'>24</xref>,<xref rid='B25' ref-type='bibr'>25</xref>].</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, pinocembrin had potent neuroprotective effects by improving mitochondrial function [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B26' ref-type='bibr'>26</xref>], decreasing oxidative damage [<xref rid='B22' ref-type='bibr'>22</xref>-<xref rid='B24' ref-type='bibr'>24</xref>], reducing neuronal apoptosis [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B23' ref-type='bibr'>23</xref>], and inhibiting inflammatory responses [<xref rid='B22' ref-type='bibr'>22</xref>] in middle cerebral artery occlusion rat models.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recently, we found that pinocembrin alleviated learning and memory deficits in a vascular dementia rat model through mitochondrial protection [<xref rid='B27' ref-type='bibr'>27</xref>], which suggests that pinocembrin has potential therapeutic effects for cognitive impairment.</s></p><fig id='F1' position='float'><label>Figure 1</label><caption><p><bold>Chemical structure of pinocembrin and the effect of pinocembrin on the behavior of amyloid-β peptide (Aβ)<sub>25-35</sub>-treated mice in Morris water maze (MWM)</bold>. <bold>(A) </bold>Structure of pinocembrin. <bold>(B) </bold>Comparison of latency to platform during 5 days of training in MWM. Acquisition training was initiated on the third day of pinocembrin oral administration (day 1 for MWM test). Daily training consisted of four trials in which the mouse was placed in the water from four random starting positions (north, east, south, and west) and the escape latency onto the platform was recorded. Data are presented as the mean ± SEM. In all 12 mice were tested per group. <bold>(C) </bold>Pinocembrin increased the percentage of time the mouse stayed in the target quadrant in the probe test. ***<italic>P </italic>&lt; 0.01 vs sham, <sup>##</sup><italic>P </italic>&lt; 0.01, <sup>###</sup><italic>P </italic>&lt; 0.001 vs Aβ<sub>25-35</sub>. Data are presented as the mean ± SEM, n = 12 mice per group. <bold>(D) </bold>Pinocembrin increased the numbers of crossings where the platform had been located in the probe test. ***<italic>P </italic>&lt; 0.01 vs sham, <sup>##</sup><italic>P </italic>&lt; 0.01 vs Aβ<sub>25-35</sub>. Data are presented as the mean ± SEM, n = 12 mice per group.</p></caption><graphic xlink:href='1741-7015-10-105-1'></graphic></fig><p><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>Even though experimental evidence suggests that pinocembrin exerts neuroprotective effects and improves cognitive function, no pre-existing study has reported the exact molecular mechanism of this compound.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Thus, as a part of our ongoing evaluating program to explore the potential mechanisms, we examined the effects of pinocembrin on improving cognitive impairment in mice induced by intracerebroventricular infusion of Aβ<sub>25-35</sub>.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Furthermore, we investigated the mechanisms underlying the efficacy of the compound on target action, mitochondrial function and potential signal transduction in different cell models using fluorescence-based multiparametric technologies with a high-content analysis platform.</s></p></sec><sec sec-type='methods'><title>Methods</title><sec><title>Animals and treatment</title><p><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Pinocembrin (high performance liquid chromatography (HPLC) purity &gt;98%) was synthesized by the Department of Medical Synthetic Chemistry, Institute of Materia Medica, Beijing, P R China.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Aβ<sub>25-35 </sub>and Aβ<sub>1-42 </sub>were purchased from Sigma Chemical Co (St Louis, MO, USA).</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Aβ<sub>25-35 </sub>was dissolved in sterile saline (1 mM) and aggregated by incubation at 37°C for 7 days before use.</s></p><p><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Male Kunming mice, 25 to 30 g, were provided by the Animal Breeding Center of the Chinese Academy of Medical Sciences.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Mice were housed five per cage and acclimated to standard laboratory conditions (12 h light, 12 h dark cycle) with free access to mouse chow and water.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The animal breeding and experiments were conducted in accordance with institutional guidelines and ethics and approved by the Laboratories Institutional Animal Care and Use Committee of Chinese Academy of Medical Sciences and Peking Union Medical College.</s></p><p><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Mice were anesthetized with 50 mg/kg sodium pentobarbital (Sigma, St. Louis, MO, USA) and placed in a stereotaxic instrument (RWD Life Science, Shenzhen, China).</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The aggregated Aβ<sub>25-35 </sub>was injected into the right lateral ventricle with the following coordinates: -0.5 mm anterior/posterior, +1.0 mm medial/lateral and -2.5 mm dorsal/ventral from Bregma (10 nmol in 3 μl of saline per injection).</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Sham animals were injected in an identical manner with the same amount of sterile saline.</s></p><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>A total of 48 mice were used, allocated to one of four groups the day after sterile saline or Aβ<sub>25-35 </sub>injection: sham group, Aβ<sub>25-35</sub>-treated group, pinocembrin 20 mg/kg group, and pinocembrin 40 mg/kg group (12 mice in each group).</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Pinocembrin was dissolved in distilled water containing 20% hydroxypropyl-β-cyclodextrin (Sigma, St Louis, MO, USA) at a concentration of 10 mg/ml, and was administered by oral gavage once a day continuously for 8 days.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The sham group and Aβ<sub>25-35</sub>-treated group received oral gavage in the same manner using distilled water containing 20% hydroxypropyl-β-cyclodextrin without pinocembrin.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After behavioral testing was completed, half the mice in each group were anaesthetized and killed by decapitation.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The brains were quickly dissected and then snap frozen in liquid nitrogen.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The brains were stored at -80°C before analysis.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The other mice in each group were anaesthetized and perfused with 0.9% saline (Beijing Chemical Works, Beijing, China) and 4% paraformaldehyde (pH 7.40~7.50; Beijing Chemical Works, Beijing, China) from the left ventricle of heart.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The division of mice into treatment groups and the selection of mice to be killed within each group were both performed randomly.</s></p></sec><sec><title>Morris water maze (MWM) performance</title><p><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The MWM task was used to evaluate the learning and memory changes in mice [<xref rid='B28' ref-type='bibr'>28</xref>].</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Briefly, maze training began on the third day of pinocembrin administration.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> In each trial, the time required to escape onto the hidden platform was recorded as escape latency.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Mice were trained for five consecutive days.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> On the ninth day of pinocembrin treatment, a single probe trial was conducted.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The time the mouse stayed in the platform quadrant and the crossings where the platform had been located were recorded.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The treatments were continued during the water maze task.</s></p></sec><sec><title>Transmission electron microscopy (TEM) assay</title><p><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>For the TEM assay, mice were anaesthetized with an intraperitoneal injection of 45 mg/kg sodium pentobarbital (Sigma, St. Louis, MO, USA).</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The heart was exposed and the left ventricle was perfused with 0.9% saline, followed by perfusion with 4% paraformaldehyde (Beijing Chemical Works, Beijing, China).</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> At the end of brain perfusion, the temporal cerebral cortices were isolated carefully and placed in fixative [approximately 20 ml of 2.5% glutaraldehyde (Merck, Darmstadt, Germany) and 2.0% paraformaldehyde (Beijing Chemical Works, Beijing, China) in 0.15 M cacodylate buffer (Merck, Darmstadt, Germany)] overnight.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Then, the samples were post-fixed in 1% osmium tetroxide (Sigma, St. Louis, MO, USA), stained in 2% uranyl acetate (Sigma, St. Louis, MO, USA), dehydrated in ethanol (Beijing Chemical Works, Beijing, China) and acetone (Beijing Chemical Works, Beijing, China), and embedded in epoxy resin (Beijing Zhongjingkeyi Technology, Beijing, China).</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Ultrathin sections (60 nm thick) were obtained of selected blocs of the samples.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The ultrathin sections were mounted on copper grids (200 mesh; Beijing Zhongjingkeyi Technology, Beijing, China) and double-contrasted with uranyl acetate and lead citrate (Sigma, St. Louis, MO, USA) for examination in a LEO 906 transmission electron microscope (Zeiss, Oberkochen, Germany) operated at 60 kV.</s></p></sec><sec><title>Fluoro-Jade B staining assay</title><p><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Fluoro-Jade B (FJB; Histochem, Jefferson, AR, USA) was used to determine neuron degeneration induced by Aβ<sub>25-35 </sub>in the cerebral cortex as described previously [<xref rid='B29' ref-type='bibr'>29</xref>,<xref rid='B30' ref-type='bibr'>30</xref>].</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Briefly, the slides were first immersed in 100% ethanol (Beijing Chemical Works, Beijing, China), followed by 70% ethanol and 30% ethanol.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> These slides were then oxidized by soaking in 0.06% potassium permanganate (Sigma, St Louis, MO, USA), and transferred to a 0.0004% FJB for 30 min.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After washing, the slides were air dried, cleared in xylene (Beijing Chemical Works, Beijing, China), and coverslipped with a mounting medium for histological detection.</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The slices were examined using an Olympus IX71 fluorescent microscope (Olympus, Tokyo, Japan) with blue excitation light and a barrier filter.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Neurons undergoing degeneration showed bright fluorescence in comparison to the background.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The number of FJB-positive neurons was counted in a section.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> In the cerebral cortex regions the number of FJB-positive neurons was calibrated as the number of neurons in 1 mm<sup>2</sup>.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Cell counts were obtained by averaging the counts from 10 sections taken from each mouse.</s></p></sec><sec><title>RNA analysis and western blot assay</title><p><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The expression of RAGE in cerebral cortex was determined by quantitative real-time polymerase chain reaction (PCR) and western blot.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Total RNA was extracted from part of the tissues using TRIzol reagents (Invitrogen, Carlsbad, CA, USA) and was processed directly to produce cDNA using TaqMan reverse transcription reagents kit (Applied Biosystems, Foster City, CA, USA).</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Quantitative real-time PCR was performed on the ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA).</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Mouse RAGE primer and probe consist of forward primer, 5'-ACAGGCGAGGGAAGGAGGTCAAGT-3'; reverse primer, 5'-TGGGCAGAGATGGCACAGGTCA-3') (Genbank: <ext-link ext-link-type='gen' xlink:href='L33412'>L33412</ext-link>). β-Actin was used as a control.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Data were calculated using the 2<sup>-ΔΔ<italic>Ct </italic></sup>method and are expressed as fold increase over the indicated controls.</s></p><p><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Other samples of the tissues were used to determine protein expression of RAGE.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Proteins were extracted from the pellets by using lysis buffer [50 mM Tris-HCl (pH 7.4; Sigma, St Louis, MO, USA), 20 mM ethylenediaminetetra-acetic acid (EDTA; Beijing Chemical Works, Beijing, China), 0.1% sodium dodecyl sulfate (SDS; Sigma, St Louis, MO, USA), 100 mM NaCl (Beijing Chemical Works, Beijing, China), 1% NP-40 (Sigma, St Louis, MO, USA), 0.5% sodium deoxycholate (Sigma, St Louis, MO, USA), 50 mM sodium fluoride (Sigma, St Louis, MO, USA), 1 mM sodium orthovanadate (Sigma, St Louis, MO, USA), 1 mM phenylmethanesulfonylfluoride (PMSF; Sigma, St Louis, MO, USA), 2 mM sodium pyrophosphate (Sigma, St Louis, MO, USA), 1 μg/ml pepstatin A (Sigma, St Louis, MO, USA), 100 μg/ml leupeptin (Sigma, St Louis, MO, USA) and one protease inhibitor cocktail tablet (1/50 ml; Roche Molecular Biochemicals, Indianapolis, IN, USA)].</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Samples were boiled for 3 min before loading onto SDS-polyacrylamide gel.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After electrophoresis, the gel was electroblotted onto polyvinylidene difluoride membranes.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Membranes were blocked in Tris-buffered saline (TBS; Sigma, St Louis, MO, USA) with 1% Tween-20 (TBST; Sigma, St Louis, MO, USA) and 5% non-fat dry milk (Sigma, St Louis, MO, USA), and then incubated with anti-RAGE (1:800, Cell Signaling Technology, Bervely, MA, USA ) overnight at 4°C.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Membranes were washed several times with TBST prior to incubation with Horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000, ZSGB-Bio, Beijing, China) for 45 min at room temperature.</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After subsequent washes in TBST, the protein bands were visualized using an ECL™ detection kit (GE Healthcare; Piscataway, NJ, USA) and exposure to X-ray films.</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Relative optical densities and areas of bands were quantified using the Image J densitometry software (version 1.6, National Institutes of Health, Bethesda, MD, USA).</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The densitometric plots of the results were normalized to the intensity of the actin band.</s></p></sec><sec><title>Cell cultures, transfections and treatments</title><p><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>U2OS cells were firstly applied to be stably transduced with a reporter plasmid (pEGFP-N1) encoding a strong response region of human RAGE promoter [<xref rid='B31' ref-type='bibr'>31</xref>] as a RAGE-overexpressing cell model, and then coincubated with pinocembrin in order to specifically dissect whether there is an effect on RAGE expression U2OS cells were grown in McCoy's 5A medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FBS; Gibco/Invitrogen, Grand Island, NY, USA) at 37°C in humidified 5% CO<sub>2 </sub>air.</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The enhanced green fluorescent protein (EGFP)-based plasmid encoding human RAGE promoter was transfected into U2OS cells and the stably expressing cells were selected by G418 resistance (Invitrogen, Carlsbad, CA, USA).</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The RAGE-overexpressing cell model was established by using Aβ<sub>1-42 </sub>to induce RAGE transcription and trigger RAGE overexpression.</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Cells were treated with 50 nM Aβ<sub>1-42 </sub>for 24 h, or coincubated Aβ<sub>1-42 </sub>with 1.0 μM, 3.0 μM, or 10.0 μM pinocembrin for 24 h.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The cells were then randomly divided into five groups: (1) RAGE control group; (2) RAGE group in the presence of 50 nM Aβ<sub>1-42 </sub>for 24 h; RAGE group in the presence of 50 nM Aβ<sub>1-42 </sub>with pinocembrin treatment at (3) 1.0 μM, (4) 3.0 μM, and (5) 10 μM for 24 h.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After the treatment, the cells were imaged and analyzed by a fluorescence-based Cellomics ArrayScan high-content screening (HCS) Reader (Thermo Fisher Scientific Cellomics, Pittsburgh, PA, USA) with the Morphology Explorer BioApplication.</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The optical fields were scanned with a 20 × objective lens to obtain a minimum of 1,000 cells per well.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The EGFP images and fluorescent intensity were acquired using a 485/20 nm excitation and 535/50 nm emission filters with a 600 ms exposure time.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The level of RAGE overexpression was illustrated by the value of mean average fluorescent intensity (Mean_AvgInten).</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Percentage of RAGE expression inhibition was calculated using the following formula: 100 × (Aβ<sub>25-35</sub>-treated Mean_AvgInten - pinocembrin-treated Mean_AvgInten) ÷ Aβ<sub>25-35</sub>-treated Mean_AvgInten.</s></p><p><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mod1' type='Mod'></CoreSc1>Human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (abbreviated to 'APPsw cells') were established as an AD cell model by using copper to trigger the neurotoxicity of Aβ.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In this model, Aβ was overproduced in the cell line but had no toxicity during cultural process in the absence of Cu<sup>2+</sup>.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In contrast, Aβ-mediated neurotoxicity was shown in the presence of Cu<sup>2+</sup>.</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mod1' type='Mod'></CoreSc1> This is an <italic>in vitro </italic>cell model for inducing Aβ-mediated neurotoxicity in which copper acts as a stimulator for Aβ when supplemented in culture medium.</s></p><p><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Cells were treated with 300 μM copper (copper sulfate, Sigma, St Louis, MO, USA) for 24 h, and then given fresh medium containing or not 1.0 μM, 3.0 μM, and 10.0 μM pinocembrin to incubate 24 h.</s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Cells were randomly divided into five groups: (1) APPsw group; (2) APPsw cells in the presence of 300 μM copper; (3) APPsw cells in the presence of 300 μM copper with pinocembrin treatment at 1.0 μM; (4) 3.0 μM; (5) 10.0 μM.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Subsequently, the cells and medium were collected for detecting the effects of pinocembrin and the potential signaling pathway.</s></p></sec><sec><title>Cell viability assay</title><p><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay was used for evaluating APPsw cell viability.</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After being treated with pinocembrin plus copper as described above, the medium was discarded and replaced with 100 μl of MTS solution (Promega, Madison, WI, USA) according to the manufacturer's protocol.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After incubation at 37°C for 1 h, absorbance at 490 nm was measured on a SpectraMax Plus microplate reader (Molecular Devices, Sunnyvale, CA, USA).</s></p></sec><sec><title>Measurements of intracellular reactive oxygen species (ROS)</title><p><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>ROS in APPsw cells were measured based on the oxidation of 2',7'-dihydrodichlorofluorescein diacetate (DCFH-DA; Sigma, St Louis, MO, USA) to 2',7'-dichlorofluorescein (DCF) [<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> DCF fluorescence intensity was detected and analyzed by a Cellomics ArrayScan V<sup>TI </sup>HCS Reader (Thermo Fisher Scientific Cellomics, Pittsburgh, PA, USA) with the Morphology Explorer BioApplication.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The cell images were acquired using a 485/20 nm excitation and 535/50 nm emission filters with a 300 ms exposure time.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The level of intracellular ROS was illustrated by the value of mean average fluorescent intensity (Mean_AvgInten).</s></p></sec><sec><title>Mitochondrial membrane potential (MMP) and superoxide detection</title><p><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The mitochondrial changes of the APPsw cells were monitored using the fluorescent dyes, Rh123 and MitoSOX Red.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The former is a cell permeable cationic dye that preferentially partitions into mitochondria based on the highly negative MMP.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Depolarization of the MMP leads to the loss of Rh123 from the mitochondrion and appears an increased intracellular fluorescence [<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The latter is a mitochondrial superoxide indicator, which is chemically targeted to mitochondria and exhibits red fluorescence when oxidized by superoxide [<xref rid='B34' ref-type='bibr'>34</xref>].</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Rh123 (Dojindo Laboratory, Kumamoto, Japan) and MitoSOX Red (Invitrogen, Carlsbad, CA, USA) were added to cell cultures to achieve a final concentration of 10 μM and 5 μM, respectively, for 30 min at 37°C after the APPsw cells were treated with pinocembrin plus copper as described above.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The nucleic acid dye Hoechst 33342 (Dojindo Laboratory, Kumamoto, Japan) was used to identify the nucleus, and was added at a final concentration of 10 μM 10 min before the Rh123 and MitoSOX Red coincubation ended.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Fluorescent images and intensities were acquired and analyzed by a Cellomics ArrayScan V<sup>TI </sup>HCS Reader (Thermo Fisher Scientific Cellomics, Pittsburgh, PA, USA) combined with the Cell Health Profiling BioApplication Guide provided with the BioApplication software.</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Hoechst 33342, Rh123 and MitoSOX Red stained images were acquired using the 386/23 nm excitation and 460/40 nm emission, 485/20 nm excitation and 535/50 nm emission, and 549/15 nm excitation and 590/50 nm emission filters, respectively.</s></p></sec><sec><title>RAGE expression analyses</title><p><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The expression of RAGE in APPsw cells was determined by quantitative real-time PCR and immunofluorescence assay.</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After the APPsw cells were treated with pinocembrin plus copper as described above, total RNA was extracted.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The human RAGE primer and probe consisted of forward primer, 5'-GATCCCCGTCCCACCTTCT-3'; reverse primer, 5'-GCTACTGCTCCACCTTCTG-3' (Genbank: <ext-link ext-link-type='gen' xlink:href='NM_001206966.1'>NM_001206966.1</ext-link>).</s></p><p><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>RAGE protein expression was examined by immunofluorescence assay.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Briefly, cells were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 (Sigma, St Louis, MO, USA), and then blocked with 3% bovine serum albumin (BSA; Sigma, St Louis, MO, USA) at room temperature.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Next, cells were incubated with primary anti-RAGE antibody, followed by Alexa Fluor 488 conjugated secondary antibody (Invitrogen, Carlsbad, CA, USA).</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Fluorescent images and intensity were acquired and quantified by a Cellomics ArrayScan V<sup>TI </sup>HCS Reader (Thermo Fisher Scientific Cellomics, Pittsburgh, PA, USA) and the Compartmental Analysis BioApplication Software Module.</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The optical fields were scanned with a 20 × objective lens to obtain a minimum of 1,000 cells per well.</s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Mean average fluorescent intensity (Mean_AvgInten) was acquired and calculated as the value of RAGE protein expression.</s></p></sec><sec><title>MAPK signal pathways, NFκB activation and apoptotic pathway assays</title><p><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The MAPK signal pathways, NFκB activation and apoptotic pathway were all detected by immunofluorescence assay and quantified on the Cellomics ArrayScan V<sup>TI </sup>high-content analysis platform, using fluorescence-based multiparametric technologies to monitor cellular constituent activities in fixed cells.</s></p><p><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>The APPsw cells were subcultured in black-walled optically clear-bottomed 96-well plates (Corning Life Sciences, Acton, MA, USA).</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After being treated with copper plus pinocembrin as described above, cells were fixed with 4% paraformaldehyde (Beijing Chemical Works, Beijing, China), permeabilized with 0.3% Triton X-100 (Sigma, St. Louis, MO, USA), and then blocked with 3% BSA (Sigma, St. Louis, MO, USA).</s><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The primary antibody mixture containing anti-phospho-p38 (Cell Signaling Technology, Bervely, MA, USA), anti-phospho-MAPKAP kinase-2 (MK2; Cell Signaling Technology, Bervely, MA, USA), anti-phospho-heat shock protein 27 (HSP27; Cell Signaling Technology, Bervely, MA, USA), anti-phospho-SAPK/JNK (Cell Signaling Technology, Bervely, MA, USA), anti-phospho-c-Jun (Cell Signaling Technology, Bervely, MA, USA), anti-phospho-p44/42 MAPK (Cell Signaling Technology, Bervely, MA, USA), anti-NFκB p65 (Cell Signaling Technology, Bervely, MA, USA), anti-B cell lymphoma 2 (Bcl-2; Cell Signaling Technology, Bervely, MA, USA), or anti-cytochrome <italic>c </italic>(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in phosphate buffered saline (PBS, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4 </sub>· 2 H<sub>2</sub>O, 2 mM KH<sub>2</sub>PO<sub>4</sub>) was incubated for 2 h at room temperature.</s><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Subsequently, cells were incubated with corresponding secondary antibodies for 1 h.</s><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The primary antibodies and corresponding secondary antibodies are listed in Table <xref rid='T1' ref-type='table'>1</xref>.</s></p><table-wrap id='T1' position='float'><label>Table 1</label><caption><p>Primary antibodies and secondary antibodies used in this study</p></caption><table rules='groups' frame='hsides'><thead><tr><th align='left'>Primary antibody</th><th align='left'>Dilution</th><th align='left'>Source</th><th align='left'>Secondary antibody (dilution, source)</th></tr></thead><tbody><tr><td align='left'>Phospho-p38 (Thr180/Tyr182) rabbit mAb</td><td align='left'>1:800</td><td align='left'>Cell Signaling Technology (CST)</td><td align='left'>Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Phospho-MK2 (Thr334) rabbit mAb</td><td align='left'>1:200</td><td align='left'>CST</td><td align='left'>Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Phospho-HSP27 (Ser82) rabbit mAb</td><td align='left'>1:50</td><td align='left'>CST</td><td align='left'>Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Phospho-SAPK/JNK (Thr183/Tyr185) mouse mAb</td><td align='left'>1:400</td><td align='left'>CST</td><td align='left'>Alexa Fluor 488 donkey anti-mouse (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Phospho-c-Jun (Ser73) mouse mAb</td><td align='left'>1:100</td><td align='left'>CST</td><td align='left'>Alexa Fluor 555 donkey anti-mouse (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Phospho-p44/42 MAPK (Thr202/Tyr204) mouse mAb</td><td align='left'>1:200</td><td align='left'>CST</td><td align='left'>Alexa Fluor 488 donkey anti-mouse (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Anti-NFκB p65 rabbit mAb</td><td align='left'>1:200</td><td align='left'>CST</td><td align='left'>Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Anti-Bcl-2 rabbit mAb</td><td align='left'>1:200</td><td align='left'>CST</td><td align='left'>Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr><tr><td align='left'>Anti-cytochrome <italic>c </italic>mouse mAb</td><td align='left'>1:400</td><td align='left'>Santa Cruz Biotechnology</td><td align='left'>Alexa Fluor 550 donkey anti-mouse (1:500, Invitrogen, Carlsbad, CA, USA)</td></tr></tbody></table></table-wrap><p><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>High content analysis was performed on the Cellomics ArrayScan V<sup>TI </sup>HCS Reader (Thermo Fisher Scientific Cellomics, Pittsburgh, PA, USA) using the Cytoplasm to Nucleus Translocation BioApplication [<xref rid='B35' ref-type='bibr'>35</xref>,<xref rid='B36' ref-type='bibr'>36</xref>].</s><s sid='145'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Briefly, images were acquired via one to three independent channels with fixed exposure times.</s><s sid='146'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Based on the Hoechst nuclear stain in channel 1, a nuclear region mask was created and used to quantify nuclear protein distribution in the other target channels.</s><s sid='147'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> By expanding the nuclear region mask, while remaining within cell boundaries, a concentric ring was generated and used as an approximation of the cytosolic compartment.</s><s sid='148'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> For HSP27 and apoptotic detection, cytosolic fluorescent intensity was acquired and calculated as the value of protein expression.</s><s sid='149'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Nuclear intensity was monitored and used for evaluating c-Jun activation.</s><s sid='150'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Cytosolic and nuclear staining intensities were normalized to the total nuclear region and cytosolic ring area; this allows for the quantification of protein translocation between the nucleus and cytosol for p38, MK2, SAPK/JNK and NFκB p65.</s><s sid='151'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The capacity of translocation of the four proteins was illustrated by the value of Mean_CircRingAvgIntenDiff.</s><s sid='152'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Following scan completion, all data were exported to an Excel<sup>® </sup>(Microsoft, Redmond, WA, USA) spreadsheet using the Cellomics vHCS View software and expressed as mean ± SEM.</s></p></sec><sec><title>Caspase 3 and caspase 9 activity assay</title><p><s sid='153'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Measurement of activity of caspase 3 and caspase 9 (Sigma, St. Louis, MO, USA) in the APPsw cells was performed using the caspase 3 and caspase 9 assay kits.</s><s sid='154'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Briefly, reactions were carried out in extraction buffer containing 200 μg of cytosolic protein extract and 40 μM Ac-DEVD p-nitroaniline or 40 μM Ac-LEHD p-nitroaniline.</s><s sid='155'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The reaction mixtures were incubated at room temperature for 2 h, and the formation of p-nitroaniline was measured at 405 nm.</s><s sid='156'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The concentration of p-nitroaniline released from the substrate was calculated from the absorbance values.</s></p></sec><sec><title>Analysis of Aβ<sub>1-42 </sub>and tumor necrosis factor α (TNFα) by enzyme-linked immunosorbent assays (ELISAs)</title><p><s sid='157'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Contents of Aβ<sub>1-42 </sub>and TNFα in culture medium of APPsw cells were measured by ELISA assays.</s><s sid='158'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Quantitative levels of Aβ and TNFα were measured according to the manufacturer's instructions (Jiameinuosi Biotech, Beijing, China).</s><s sid='159'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The optical density was measured at 450 nm, and values qualified from a standard curve generated with the limits of detection of 5 pg/ml for Aβ<sub>1-42 </sub>and 7 pg/ml for TNFα.</s></p></sec><sec><title>Statistics</title><p><s sid='160'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>All data are represented as the mean ± SEM.</s><s sid='161'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Statistical significance was set at <italic>P </italic>&lt; 0.05.</s><s sid='162'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Statistical analyses were performed on computer using the SPSS software (Version 13.0; SPSS, Inc., Chicago, IL, USA).</s><s sid='163'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Treatment differences in the escape latency in the MWM task were analyzed using two-factor analysis of variance with repeated measures on one factor.</s><s sid='164'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Tukey's <italic>post hoc </italic>test was used if the treatment and/or the treatment × day interaction were significant on analysis of variance (ANOVA).</s><s sid='165'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The other studies were analyzed using one-way ANOVA followed by an appropriate <italic>post hoc </italic>test to analyze the difference.</s><s sid='166'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Each of the <italic>in vitro </italic>experiments was repeated at least three times.</s></p></sec></sec><sec sec-type='results'><title>Results</title><sec><title>Pinocembrin inhibited RAGE-induced p38MAPK and SAPK/JNK pathways of APPsw cells, not p44/42 MAPK in the presence of copper</title><sec><title>Oral pinocembrin treatment ameliorated the spatial learning and memory deficits against A<bold>β</bold><sub>25-35</sub>-induced toxicity</title><p><s sid='167'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Spatial learning was initiated on the third day of pinocembrin treatment (day 1 for MWM test) and assessed by the time required to find the hidden platform (escape latency).</s><s sid='168'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Figure <xref rid='F1' ref-type='fig'>1B</xref> shows the results of all mice during acquisition training.</s><s sid='169'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Repeated-measures ANOVA revealed a significant day effect on escape latency (<italic>F</italic><sub>(4,176) </sub>= 8.39, <italic>P </italic>&lt; 0.001) within the groups, indicating that all pinocembrin-treated mice improved their spatial learning effectively across the 5-day training period.</s><s sid='170'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> There was also a significant treatment effect (<italic>F</italic><sub>(3,44) </sub>= 16.68; <italic>P </italic>&lt; 0.001) on the escape latency, and subsequent comparisons further suggested that 20 mg/kg and 40 mg/kg pinocembrin treatment reduced the escape latency in comparison to the Aβ<sub>25-35 </sub>group (20 mg/kg, <italic>P</italic>&lt; 0.01; 40 mg/kg pinocembrin, <italic>P</italic>&lt; 0.001) during the 5-day acquisition training, which demonstrated that pinocembrin was effective in attenuating spatial learning deficits in Aβ<sub>25-35</sub>-treated mice.</s><s sid='171'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> There was no significance in the interactions of treatment and days (<italic>F</italic><sub>(12,176) </sub>= 0.85, <italic>P </italic>&gt; 0.05).</s></p><p><s sid='172'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Furthermore, we investigated the effects of pinocembrin on spatial memory deficits.</s><s sid='173'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Probe trials were conducted on the ninth day of pinocembrin treatment (day 6 for MWM test) to assess the spatial memory.</s><s sid='174'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The length of time the mouse stayed in the target quadrant and the numbers of crossings where the platform had been located were both recorded.</s><s sid='175'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As shown in Figure <xref rid='F1' ref-type='fig'>1C,D</xref>, the Aβ<sub>25-35</sub>-treated mice spent significantly less time searching for the platform in the target quadrant and showed less numbers of crossings where the platform had been previously relative to the sham mice (<italic>P </italic>&lt; 0.001, <italic>P </italic>&lt; 0.001).</s><s sid='176'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, pinocembrin-treated mice spent more time searching in the target quadrant as compared to the Aβ<sub>25-35</sub>-treated mice (<italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001).</s><s sid='177'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Pinocembrin treatment at 40 mg/kg also increased the numbers of crossings where the platform was located (<italic>P </italic>&lt; 0.01).</s><s sid='178'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> These results demonstrated that pinocembrin improved spatial memory against Aβ<sub>25-35</sub>-induced toxicity.</s></p></sec><sec><title>Oral pinocembrin treatment protected cerebral cortex ultrastructure against A<bold>β</bold><sub>25-35</sub>-induced toxicity</title><p><s sid='179'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>To further observe the morphological changes of the cerebral cortex, selected cortex pieces were viewed under a transmission electron microscope.</s><s sid='180'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The cerebral cortices of sham mice were characterized by the normal appearance of neurons and surrounding astrocytes (Figure <xref rid='F2' ref-type='fig'>2A, a,b</xref>).</s><s sid='181'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Neurons (N) showed neither swelling nor shrinkage (Figure <xref rid='F2' ref-type='fig'>2A, a</xref>).</s><s sid='182'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Astrocytes (As) did not exhibit any apparent signs of perivascular edema (Figure <xref rid='F2' ref-type='fig'>2A, b</xref>).</s><s sid='183'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The neuropil appeared compact.</s><s sid='184'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the cortices of Aβ<sub>25-35</sub>-treated mice, neuronal degeneration in the cortex was observed (Figure <xref rid='F2' ref-type='fig'>2A, c,d</xref>).</s><s sid='185'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The cell membranes of neurons were ruptured, and the cell cytoplasm showed dark and dense granules (Figure <xref rid='F2' ref-type='fig'>2A, c</xref>).</s><s sid='186'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The nucleolus showed degenerative changes and the karyoplasms were filled with dense materials (Figure <xref rid='F2' ref-type='fig'>2A, c</xref>).</s><s sid='187'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Intracellular vacuolation and edema of astrocytes around neurons as well as adjacent degeneration of the neuropil were clearly visible (Figure <xref rid='F2' ref-type='fig'>2A, d</xref>).</s><s sid='188'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin treatment at 20 mg/kg and 40 mg/kg markedly attenuated neuropil damage in the cortex.</s><s sid='189'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Neuronal pycnosis was relieved (Figure <xref rid='F2' ref-type='fig'>2A, e,g</xref>).</s><s sid='190'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The swelling of As and disintegration of the astrocytic cytoplasm were less apparent (Figure <xref rid='F2' ref-type='fig'>2A, f,h</xref>).</s><s sid='191'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Signs of membrane damage and vacuolation were less apparent.</s></p><fig id='F2' position='float'><label>Figure 2</label><caption><p><bold>Pinocembrin protected cerebral cortex ultrastructure and inhibited receptor for advanced glycation end products (RAGE) expression against amyloid-β peptide (Aβ)<sub>25-35</sub>-induced toxicity</bold>. <bold>(A) </bold>Ultrastructural analysis of cerebral cortex against Aβ<sub>25-35</sub>-induced toxicity. (a,b) The representative area of sham mice cortex was characterized by the normal appearance of neurons, surrounding astrocytes and neuropil. Neurons (N) showed neither swelling nor shrinkage. Astrocytes (As) did not exhibit any apparent signs of perivascular edema. The neuropil appeared compact. (c,d) In the cortex of Aβ<sub>25-35</sub>-treated mice, neurons (N) showed degenerative changes. The cell membrane was ruptured, and the cell cytoplasm showed dark and dense granules. The nucleolus showed degenerative changes and the karyoplasm was filled with dense materials. Astrocyte (As) foot surrounding the neuron appeared swollen, producing an area of lower tissue density. (e,f) The 40 mg/kg pinocembrin treatment markedly attenuated damage of neuropil in the cortex. Neuronal pycnosis was relieved. The swelling of astrocytes (As) and disintegration of astrocytic cytoplasm was less apparent. (g,h) The 20 mg/kg pinocembrin treatment also alleviated neuronal pycnosis, and the neuropil in the treatment group appeared compact. <bold>(B) </bold>Fluoro-Jade B staining assay for cortical neuronal degeneration in Aβ<sub>25-35</sub>-infused mice. (a), sham; (b), Aβ<sub>25-35</sub>; (c), 20 mg/kg pinocembrin treatment; (d), 40 mg/kg pinocembrin treatment (× 100); (e), mean number of Fluoro-Jade B positive cells/mm<sup>2 </sup>of the cerebral cortex. Data are presented as the mean ± SEM, n = 4, ***<italic>P </italic>&lt; 0.001 vs sham, <sup>#</sup><italic>P </italic>&lt; 0.05, <sup>###</sup><italic>P </italic>&lt; 0.001 vs Aβ<sub>25-35</sub>. <bold>(C) </bold>Quantitative real-time polymerase chain reaction (PCR) for mouse RAGE mRNA in cerebral cortex in Aβ<sub>25-35</sub>-infused mice. Data are presented as the mean ± SEM, n = 5, ***<italic>P </italic>&lt; 0.001 vs sham, <sup>###</sup><italic>P </italic>&lt; 0.001 vs Aβ<sub>25-35</sub>. <bold>(D) </bold>Western blot analysis for mouse RAGE protein in cerebral cortex in Aβ<sub>25-35</sub>-infused mice. Data are presented as the mean ± SEM, n = 5, ***<italic>P </italic>&lt; 0.001 vs sham, <sup>###</sup><italic>P </italic>&lt; 0.001 vs Aβ<sub>25-35</sub>.</p></caption><graphic xlink:href='1741-7015-10-105-2'></graphic></fig></sec><sec><title>Oral pinocembrin treatment inhibited neuronal degeneration in cerebral cortex against A<bold>β</bold><sub>25-35</sub>-induced toxicity</title><p><s sid='192'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>FJB is a very useful maker for neuronal degeneration [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='193'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the sham group, FJB-positive neurons were hardly observed in the cerebral cortex (Figure <xref rid='F2' ref-type='fig'>2B, a</xref>).</s><s sid='194'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, FJB-positive neurons were dramatically increased in the cerebral cortex of the Aβ<sub>25-35 </sub>group (<italic>P </italic>&lt; 0.001, Figure <xref rid='F2' ref-type='fig'>2B, b,e</xref>).</s><s sid='195'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin treatment significantly inhibited neuronal degeneration in the cerebral cortex, showing a decreased number of FJB-positive neurons in the pinocembrin-treated groups (<italic>P </italic>&lt; 0.05, <italic>P </italic>&lt; 0.001, Figure <xref rid='F2' ref-type='fig'>2B, c-e</xref>).</s><s sid='196'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This result suggests that pinocembrin was effective in inhibiting the Aβ<sub>25-35</sub>-induced neuronal degeneration.</s></p></sec><sec><title>Oral pinocembrin treatment inhibit RAGE expression in cerebral cortex against A<bold>β</bold><sub>25-35</sub>-induced toxicity</title><p><s sid='197'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>To assess the RAGE changes in the cerebral cortex, transcription and protein expression were studied following behavioral tests.</s><s sid='198'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> An increased fold level of RAGE transcripts was observed in the cerebral cortex of Aβ<sub>25-35</sub>-treated mice (<italic>P </italic>&lt; 0.001, Figure <xref rid='F2' ref-type='fig'>2C</xref>).</s><s sid='199'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Western blot studies displayed increased RAGE protein expression in the cerebral cortex (<italic>P </italic>&lt; 0.001, Figure <xref rid='F2' ref-type='fig'>2D</xref>), which was consistent with the changes of the level of RAGE transcripts.</s><s sid='200'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin treatment significantly inhibited the upregulation of RAGE transcripts in accordance with its protein expression in a dose-dependent manner (<italic>P </italic>&lt; 0.001, Figure <xref rid='F2' ref-type='fig'>2C,D</xref>), suggesting that pinocembrin was effective in inhibiting the overexpression of RAGE in Aβ<sub>25-35</sub>-treated mice.</s></p></sec></sec><sec><title>Pinocembrin increased cell viability, but did not attenuate Aβ<sub>1-42 </sub>secretion and scavenge intracellular ROS of APPsw cells in the presence of copper</title><p><s sid='201'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>In order to better resemble the <italic>in vivo </italic>Aβ-induced neurotoxicity, instead of directly using single Aβ treatment, we used a copper-treated APPsw overexpressing cell system [<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='202'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As shown in Figure <xref rid='F3' ref-type='fig'>3A</xref>, cell viability was significantly decreased in the presence of 300 μM copper in APPsw cells (<italic>P </italic>&lt; 0.001).</s><s sid='203'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Pinocembrin enhanced the cell viability at 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner (<italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, <italic>P </italic>&lt; 0.001).</s><s sid='204'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Pinocembrin did not show a significant effect in the APPsw cells without copper treatment for 24 h.</s></p><fig id='F3' position='float'><label>Figure 3</label><caption><p><bold>Pinocembrin restored cell viability, but did not inhibit amyloid-β peptide (Aβ)<sub>1-42 </sub>secretion and scavenge intracellular reactive oxygen species (ROS) of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper</bold>. <bold>(A) </bold>Neuroprotective effects of pinocembrin evaluated by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control, <sup>##</sup><italic>P </italic>&lt; 0.01, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper. <bold>(B) </bold>Effects of pinocembrin on Aβ<sub>1-42 </sub>secretion of APPsw cells in the presence of copper. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control. <bold>(C,D) </bold>Effects of pinocembrin on intracellular ROS generation in APPsw cells in the presence of copper. Intracellular ROS levels were determined based on the 2',7'-dichlorofluorescein (DCF) fluorescence on the ArrayScan high-content screening (HCS) Reader with the Morphology Explorer BioApplication. (a), APPsw group; (b), APPsw cells in the presence of 300 μM copper; (c), APPsw cells in the present of 300 μM copper with pinocembrin treatment at 1.0 μM; (d), 3.0 μM; (e), 10.0 μM. Data are expressed as mean ± SEM, n = 6, **<italic>P </italic>&lt; 0.01 vs control.</p></caption><graphic xlink:href='1741-7015-10-105-3'></graphic></fig><p><s sid='205'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Copper is one of the redox metals, capable of increasing oxidative stress with the production of excess superoxide and hydroxyl radicals due to the overproduction of Aβ [<xref rid='B37' ref-type='bibr'>37</xref>], and thus is associated with the severe redox imbalance in this cell model [<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='206'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Copper increased the Aβ<sub>1-42 </sub>and ROS generation by about a 4.2-fold and 3.3-fold increase, respectively (<italic>P </italic>&lt; 0.01, Figure <xref rid='F3' ref-type='fig'>3B-D</xref>).</s><s sid='207'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, pinocembrin could not significantly inhibit Aβ<sub>1-42 </sub>secretion and scavenge the ROS generation in the present model at the each concentration, which indicated that pinocembrin did not have a sufficient effect on decreasing Aβ<sub>1-42 </sub>secretion and ameliorating the antioxidative ability in APPsw cells subjected to Aβ-induced neurotoxicity triggered by copper.</s></p></sec><sec><title>Pinocembrin inhibited RAGE expression both in RAGE-overexpression cells and APPsw cells in the presence of copper</title><p><s sid='208'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>To further verify the expression of RAGE and the effect of pinocembrin, we used an Aβ<sub>1-42</sub>-treated RAGE overexpressing cell model, where the RAGE expression could be elevated by excessive amounts of Aβ.</s><s sid='209'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Meanwhile, we also detected the levels of RAGE mRNA and protein in an AD cell model by using copper to trigger the neurotoxicity of Aβ.</s></p><p><s sid='210'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>As shown in Figure <xref rid='F4' ref-type='fig'>4A,B</xref>, Aβ<sub>1-42 </sub>triggered the upregulation of RAGE by about a 3.77-fold increase in Mean_AvgInten values (<italic>P </italic>&lt; 0.001) in the present model.</s><s sid='211'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Pinocembrin inhibited the overexpression of RAGE (<italic>P </italic>&lt; 0.001).</s><s sid='212'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The inhibition values of pinocembrin are 59.66% ± 2.06%, 65.89% ± 1.46% and 71.51% ± 0.98% at the concentrations of 1.0 μM, 3.0 μM and 10.0 μM, respectively.</s><s sid='213'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In addition, Aβ<sub>1-42 </sub>induced RAGE transcription without any cell viability influence due to non-significant changes on nuclear number and fluorescent intensity in RAGE-expressing cells for 24 h, and pinocembrin did not show significant effects on RAGE-expressing cell numbers in the same manner (Figure <xref rid='F4' ref-type='fig'>4C,D</xref>).</s><s sid='214'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> This phenomenon might suggest that pinocembrin has a direct inhibitory effect on RAGE expression, probably not dependent on the proliferation of the cells.</s></p><fig id='F4' position='float'><label>Figure 4</label><caption><p><bold>Pinocembrin inhibited receptor for advanced glycation end products (RAGE) expression in RAGE-overexpression cells and in human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper</bold>. <bold>(A) </bold>Effects of pinocembrin on RAGE expression in RAGE-overexpression cells. <bold>(B) </bold>Mean_AvgInten value of enhanced green fluorescent protein (EGFP)-RAGE in RAGE-overexpression cells being exposed to amyloid-β peptide (Aβ)<sub>1-42 </sub>for 24 h. Inhibition of RAGE expression results in changes of Mean_AvgInten value of EGFP-RAGE. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control, <sup>###</sup><italic>P </italic>&lt; 0.001 vs Aβ<sub>1-42</sub>. <bold>(C) </bold>Nuclear Mean_AvgInten value in RAGE-overexpression cells cocultured with pinocembrin for 24 h. Data are expressed as mean ± SEM, n = 6. <bold>(D) </bold>Cell numbers per 20 fields of RAGE-overexpression cells cocultured with pinocembrin for 24 h. Data are expressed as mean ± SEM, n = 6. <bold>(E) </bold>Effects of pinocembrin on RAGE expression in APPsw cells in the presence of copper. <bold>(F) </bold>Mean_AvgInten value of EGFP-RAGE in RAGE-overexpression cells being exposed to Aβ<sub>1-42 </sub>for 24 h. Inhibition of RAGE expression results in changes of Mean_AvgInten value of EGFP-RAGE. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper. <bold>(G) </bold>Quantitative real-time polymerase chain reaction (PCR) for human RAGE mRNA in APPsw cells in the presence of copper. Data are presented as the mean ± SEM, n = 6, **<italic>P </italic>&lt; 0.01 vs control, <sup>#</sup><italic>P </italic>&lt; 0.05, <sup>##</sup><italic>P </italic>&lt; 0.01 vs copper.</p></caption><graphic xlink:href='1741-7015-10-105-4'></graphic></fig><p><s sid='215'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Immunofluorescence assays and quantitative real-time PCR showed a 2.8-fold increase in Mean_AvgInten values of RAGE expression and an eightfold increase level of RAGE transcripts in copper-treated APPsw cells (<italic>P </italic>&lt; 0.001, <italic>P </italic>&lt; 0.01, Figure <xref rid='F4' ref-type='fig'>4E-G</xref>).</s><s sid='216'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin treatments significantly inhibited RAGE protein expression in accordance with the downregulation of the transcripts at concentrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner (<italic>P </italic>&lt; 0.05, <italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, Figure <xref rid='F4' ref-type='fig'>4E-G</xref>), suggesting that pinocembrin was prominent in inhibiting the overexpression of RAGE in copper-treated APPsw cells.</s></p></sec><sec><title>Pinocembrin inhibited RAGE-induced p38MAPK and SAPK/JNK pathways of APPsw cells, not p44/42 MAPK in the presence of copper</title><p><s sid='217'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Aβ-RAGE signaling is a mediator in the phosphorylation state of MAPKs.</s><s sid='218'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Total p38MAPK cellular distribution and expression levels are thought to modulate the downstream highly expressed substrate MK2, and subsequently HSP27.</s><s sid='219'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In control cells, basal levels of phospho-p38 and phospho-MK2 were significantly confined to the cytosolic and nuclear compartment, showing negative and high Mean_CircRingAvgIntenDiff values, respectively.</s><s sid='220'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The downstream phospho-HSP27 showed correspondingly weak staining, showing a low cytosolic Mean_AvgInten value.</s><s sid='221'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In copper-treated APPsw cells, the capacity of copper to promote phospho-p38 and phospho-MK2 translocation was illustrated by a significant increase and a remarkable decrease in Mean_CircRingAvgIntenDiff values, respectively (<italic>P </italic>&lt; 0.001, <italic>P </italic>&lt; 0.01, Figure <xref rid='F5' ref-type='fig'>5A-C</xref>).</s><s sid='222'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Similarly, the downstream phospho-HSP27 showed strong fluorescence with a 3.74-fold increase in cytosolic Mean_AvgInten values (<italic>P </italic>&lt; 0.001, Figure <xref rid='F5' ref-type='fig'>5A,D</xref>).</s><s sid='223'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin treatments significantly inhibited the p38MAPK signal pathway.</s><s sid='224'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The translocation of cytosolic phospho-p38 to the nucleus and nuclear phospho-MK2 to the cytoplasm were significantly inhibited in accordance with the downregulation of downstream phospho-HSP27 at the concentrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner (<italic>P </italic>&lt; 0.05, <italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, Figure <xref rid='F5' ref-type='fig'>5</xref>).</s></p><fig id='F5' position='float'><label>Figure 5</label><caption><p><bold>Pinocembrin inhibited receptor for advanced glycation end products (RAGE)-induced p38 mitogen-activated protein kinase (MAPK)-MAPKAP kinase-2 (MK2)-heat shock protein 27 (HSP27) pathway of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper</bold>. <bold>(A) </bold>Images of p38MAPK-MK2-HSP27 pathways performed by high content analysis on the ArrayScan high-content screening (HCS) Reader using the Cytoplasm to Nucleus Translocation BioApplication. APPsw cells were treated plus copper as described in the Methods, prior to fixation, permeabilization, Hoechst nuclear staining, and immunolabeling with antibodies targeting phospho-p38MAPK, phospho-MK2, and phospho-HSP27. Each column reflects images collected from the respective fluorescent channels. <bold>(B,C) </bold>Values of Mean_CircRingAvgIntenDiff describing the capacity translocation of cytosolic phospho-p38 to the nucleus and nuclear phospho-MK2 to the cytoplasm. <bold>(D) </bold>Cytosolic Mean_AvgInten value illustrating the expression of phospho-HSP27. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control, <sup>#</sup><italic>P </italic>&lt; 0.05, <sup>##</sup><italic>P </italic>&lt; 0.01, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper.</p></caption><graphic xlink:href='1741-7015-10-105-5'></graphic></fig><p><s sid='225'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>As a consequence of Aβ-RAGE interaction, activation of SAPK/JNK and p44/42 MAPK pathways was also observed.</s><s sid='226'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The basal level of phospho-SAPK/JNK and phospho-p44/42 MAPK was both confined to the cytosolic compartment, shown as negative Mean_CircRingAvgIntenDiff values in control cells.</s><s sid='227'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In copper-treated cells, phospho-SAPK/JNK and phospho-p44/42 MAPK translocation was promoted by a significant increase in Mean_CircRingAvgIntenDiff values, respectively (<italic>P </italic>&lt; 0.001, Figure <xref rid='F6' ref-type='fig'>6A,B,D</xref>).</s><s sid='228'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The level of phospho-c-Jun was shown by consistent changes in Mean_AvgInten values in the nucleus (<italic>P </italic>&lt; 0.01, Figure <xref rid='F6' ref-type='fig'>6A,C</xref>).</s><s sid='229'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin treatments significantly inhibited the SAPK/JNK pathway.</s><s sid='230'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The translocation of cytosolic phospho-SAPK/JNK to the nucleus and the downregulation of its downstream phospho-c-Jun were both inhibited at the concentrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner (<italic>P </italic>&lt; 0.05, <italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, Figure <xref rid='F6' ref-type='fig'>6A-C</xref>).</s><s sid='231'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However pinocembrin did not show a significant effect on phospho-p44/42 MAPK nuclear translocation.</s></p><fig id='F6' position='float'><label>Figure 6</label><caption><p><bold>Pinocembrin inhibited receptor for advanced glycation end products (RAGE)-induced stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) pathway, but not p44/42 mitogen-activated protein kinase (MAPK) pathway of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper</bold>. <bold>(A) </bold>Images of SAPK/JNK and p44/42 MAPK pathways evaluated by high content analysis on the ArrayScan high-content screening (HCS) Reader using the Cytoplasm to Nucleus Translocation BioApplication. <bold>(B,D) </bold>Values of Mean_CircRingAvgIntenDiff describing the capacity translocation of cytosolic phospho-JNK and phospho-p44/42 MAPK to the nucleus. <bold>(C) </bold>Nuclear Mean_AvgInten value illustrating the expression of phospho-c-Jun. Data are expressed as mean ± SEM, n = 6, **<italic>P </italic>&lt; 0.01, ***<italic>P </italic>&lt; 0.001 vs control, <sup>#</sup><italic>P </italic>&lt; 0.05, <sup>##</sup><italic>P </italic>&lt; 0.01, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper.</p></caption><graphic xlink:href='1741-7015-10-105-6'></graphic></fig></sec><sec><title>Pinocembrin inhibited the NFκB p65 translocation and the release of inflammatory cytokines in APPsw cells in the presence of copper</title><p><s sid='232'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>NFκB activity was analyzed by quantifying the translocation of cytosolic p65 to the nucleus.</s><s sid='233'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As shown in Figure <xref rid='F7' ref-type='fig'>7A,B</xref>, basal p65 was mainly distributed in the cytoplasm, and Mean_CircRingAvgIntenDiff values were negative in control cells.</s><s sid='234'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p65 translocation from the cytoplasm to the nucleus was caused in the copper-treated cells.</s><s sid='235'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Mean_CircRingAvgIntenDiff values drastically increased from -8.21 ± 0.85 in control cells to 44.14 ± 1.21 in copper-treated cells (<italic>P </italic>&lt; 0.001, Figure <xref rid='F7' ref-type='fig'>7A,B</xref>).</s><s sid='236'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This translocation was significantly inhibited by pinocembrin treatment.</s><s sid='237'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The translocation of p65 to the nucleus was inhibited at the concentrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner (<italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.01, Figure <xref rid='F7' ref-type='fig'>7A,B</xref>).</s></p><fig id='F7' position='float'><label>Figure 7</label><caption><p><bold>Pinocembrin inhibited the nuclear factor κB (NFκB) p65 translocation and the release of inflammatory cytokines of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper</bold>. <bold>(A) </bold>Images of NFκB p65 translocation in the same field. NFκB activity was analyzed on the ArrayScan high-content screening (HCS) Reader to quantify the translocation of cytosolic p65 to the nucleus. <bold>(B) </bold>The value of Mean_CircRingAvgIntenDiff describing the translocation capacity of cytosolic p65 to the nucleus. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control, <sup>##</sup><italic>P </italic>&lt; 0.01 vs copper. <bold>(C) </bold>Content of tumor necrosis factor α (TNFα) in APPsw cell culture supernatant after being exposed to copper. Data are expressed as mean ± SEM, n = 4, ***<italic>P </italic>&lt; 0.001 vs control, <sup>#</sup><italic>P </italic>&lt; 0.05, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper.</p></caption><graphic xlink:href='1741-7015-10-105-7'></graphic></fig><p><s sid='238'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The values of TNFα in APPsw cell culture supernatant changed in the same way.</s><s sid='239'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> APPsw cells increased the generation of TNFα following copper treatment, but the secretions were significantly attenuated by pinocembrin at 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner (<italic>P </italic>&lt; 0.05, <italic>P </italic>&lt; 0.001, <italic>P </italic>&lt; 0.001, Figure <xref rid='F7' ref-type='fig'>7C</xref>).</s></p></sec><sec><title>Pinocembrin protected mitochondrial function and inhibited mitochondrion-induced apoptosis</title><p><s sid='240'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The mitochondrial function of the APPsw cells was monitored using the fluorescent dyes Rh123 and MitoSOX Red.</s><s sid='241'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The fluorescence of Rh123 and MitoSOX Red were evaluated by Mean_AvgInten values collected from the respective fluorescent channels using the same optical field.</s><s sid='242'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> After incubation with copper for 24 h, the Mean_AvgInten values of Rh123 and MitoSOX red increased to 59.61% and 196.17% above control cells, respectively (<italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, Figure <xref rid='F8' ref-type='fig'>8A-C</xref>).</s><s sid='243'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> These data represented a loss of MMP and a special oxidation of mitochondria.</s><s sid='244'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin alleviated mitochondrial dysfunction remarkably.</s><s sid='245'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Treatment at 1.0 μM, 3.0 μM and 10.0 μM reduced the respective Mean_AvgInten value in a dose-dependent manner (<italic>P </italic>&lt; 0.05, <italic>P </italic>&lt; 0.001, Figure <xref rid='F8' ref-type='fig'>8A-C</xref>).</s></p><fig id='F8' position='float'><label>Figure 8</label><caption><p><bold>Pinocembrin protected mitochondrial function and inhibited nuclear apoptosis</bold>. <bold>(A) </bold>Fluorescent images of mitochondrial function and nuclear changes in the same field. The mitochondria were monitored using the fluorescent dyes, Rh123 and MitoSOX Red, in living cells. Fluorescent images and intensities were acquired and analyzed by a Cellomics ArrayScan high-content screening (HCS) Reader combined with the Cell Health Profiling BioApplication Guide provided with the BioApplication software. <bold>(B-D) </bold>Values of Mean_AvgInten of Rh123, MitoSOX Red and Hoechst 33342 collected from the respective fluorescent channels using the same optical field. Data are expressed as mean ± SEM, n = 6, **<italic>P </italic>&lt; 0.01, ***<italic>P </italic>&lt; 0.001 vs control, <sup>#</sup><italic>P </italic>&lt; 0.05, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper.</p></caption><graphic xlink:href='1741-7015-10-105-8'></graphic></fig><p><s sid='246'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>The cytoprotective effects of pinocembrin were also confirmed by Hoechst 33342 staining.</s><s sid='247'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As shown in Figure <xref rid='F8' ref-type='fig'>8A,D</xref>, copper-treated APPsw cells contained condensed or fragmented nuclei with strong bright Hoechst staining (<italic>P </italic>&lt; 0.001).</s><s sid='248'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, pinocembrin attenuated nuclear condensation shown as lowered nuclear Mean_AvgInten values (<italic>P </italic>&lt; 0.001).</s></p><p><s sid='249'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Mitochondrial dysfunction, caspase-dependent toxicity, and downstream signaling pathways are documented as critical apoptotic events during AD processes.</s><s sid='250'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The release of cytochrome <italic>c</italic>, the expression of Bcl-2, and the cytosolic activity of caspase 3 and caspase 9 were detected as mitochondrial related apoptotic molecular makers.</s><s sid='251'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The two formers were measured by immunofluorescence labeling by quantifying the Mean_AvgInten values in the same optical field.</s><s sid='252'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The Mean_AvgInten values of Bcl-2 saw a significant decrease, while the values of cytochrome <italic>c </italic>saw a two-fold increase (<italic>P </italic>&lt; 0.001, Figure <xref rid='F9' ref-type='fig'>9A-C</xref>).</s><s sid='253'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Pinocembrin caused the restoration of Bcl-2 and cytochrome <italic>c </italic>(<italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, Figure <xref rid='F9' ref-type='fig'>9A-C</xref>).</s><s sid='254'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Similarly, the activities of caspase 3 and caspase 9 were both increased in APPsw cells in the presence of copper, but they were significantly suppressed by pinocembrin treatment (<italic>P </italic>&lt; 0.01, <italic>P </italic>&lt; 0.001, Figure <xref rid='F9' ref-type='fig'>9D</xref>).</s><s sid='255'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> These restorative effects were significant at the concentrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-dependent manner.</s></p><fig id='F9' position='float'><label>Figure 9</label><caption><p><bold>Pinocembrin inhibited mitochondrion-induced apoptosis</bold>. <bold>(A) </bold>Fluorescent images of B cell lymphoma 2 (Bcl-2), cytochrome <italic>c </italic>and nucleus in the same field. <bold>(B,C) </bold>Values of Mean_AvgInten of Bcl-2 and cytochrome <italic>c </italic>collected from the respective fluorescent channels using the same optical field. Data are expressed as mean ± SEM, n = 6, ***<italic>P </italic>&lt; 0.001 vs control, <sup>##</sup><italic>P </italic>&lt; 0.01, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper. <bold>(D) </bold>Activity of caspase 3 and caspase 9 of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper. Data are expressed as mean ± SEM, n = 4, ***<italic>P </italic>&lt; 0.001 vs control, <sup>##</sup><italic>P </italic>&lt; 0.01, <sup>###</sup><italic>P </italic>&lt; 0.001 vs copper.</p></caption><graphic xlink:href='1741-7015-10-105-9'></graphic></fig></sec></sec><sec sec-type='discussion'><title>Discussion</title><p><s sid='256'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>There are three major findings from the present study.</s><s sid='257'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> First, pinocembrin, for the first time, is shown to be a promising drug candidate for the treatment of AD as it is shown to alleviate the cognitive deficits induced by Aβ<sub>25-35 </sub>intracerebroventricular infusion in mice <italic>in vivo </italic>and reduce neuronal damage and degeneration mediated by Aβ in the presence of copper <italic>in vitro</italic>.</s><s sid='258'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Second, the survival signaling pathways of the actual therapeutic value of pinocembrin have been demonstrated through inactivation of RAGE-dependent signaling pathways and inhibition of mitochondrion-mediated apoptosis against Aβ-mediated neurotoxicity.</s><s sid='259'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Third, RAGE was used as a therapeutic target for evaluation of the efficacy of compounds, and an effective inhibitory effect of pinocembrin was illustrated, as well as the subsequent inactivation of p38MAPK, SAPK/JNK pathways and the downstream inflammatory response.</s></p><p><s sid='260'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The toxic effects of Aβ on the cholinergic system and cognitive function are variable, due to the differences in the sites of administration and experimental models [<xref rid='B38' ref-type='bibr'>38</xref>-<xref rid='B44' ref-type='bibr'>44</xref>].</s><s sid='261'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The neurotoxicity of Aβ interrelated with senile plaques in AD brains is linked to the amino acids located in positions 25 to 35 of the full length protein [<xref rid='B45' ref-type='bibr'>45</xref>,<xref rid='B46' ref-type='bibr'>46</xref>].</s><s sid='262'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In order to investigate the prospective therapeutic value of pinocembrin on cognitive impairment and neuronal apoptosis in correlation with neurodegeneration in AD, Aβ neurotoxicity induced learning and memory deficits and neuronal injury were established by a single intracerebroventricular infusion of Aβ<sub>25-35</sub>, an Aβ<sub>1-42</sub>-treated RAGE overexpressing cell model, and a copper-treated APPsw overexpressing cell system, all of which could well reflect Aβ toxicity in an Aβ-rich environment both <italic>in vivo </italic>and <italic>in vitro</italic>.</s></p><p><s sid='263'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Intracerebroventricular infusion of Aβ<sub>25-35 </sub>was demonstrated to induce spatial learning and memory impairment in AD animal models [<xref rid='B41' ref-type='bibr'>41</xref>-<xref rid='B44' ref-type='bibr'>44</xref>].</s><s sid='264'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Herein, a single intracerebroventricular injection of Aβ<sub>25-35 </sub>in mice induced significant amnesia as compared to the sterile saline -injected sham group.</s><s sid='265'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This confirmed that cognitive impairment was induced by Aβ<sub>25-35 </sub>peptide itself, and was not attributable to an intracerebroventricular injection.</s><s sid='266'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our results showed that pinocembrin, taken by oral gavage of 20 mg/kg/day and 40 mg/kg/day, improved spatial learning effectively across the 5-day acquisition training period.</s><s sid='267'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The Aβ<sub>25-35</sub>-administered mice after pinocembrin treatment showed a better learning capability in finding the hidden platform by reduction of escape latency.</s><s sid='268'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In the memory probe trial, the Aβ<sub>25-35</sub>-treated mice receiving pinocembrin treatment performed much better in searching for the target quadrant and the site where the platform was located as compared to the Aβ<sub>25-35</sub>-administered mice.</s></p><p><s sid='269'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Cerebral histomorphological or functional anomalies could be a sign of the pathogenesis of neurodegeneration, accompanied by cognitive disorder in AD patients [<xref rid='B47' ref-type='bibr'>47</xref>].</s><s sid='270'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our study further confirmed that pinocembrin preserved the ultrastructural changes of neurons and surrounding astrocytes in the cerebral cortex as well.</s><s sid='271'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Both 20 mg/kg and 40 mg/kg pinocembrin treatment protected the neuropil from Aβ<sub>25-35</sub>-induced toxicity, characterized by the relatively normal appearance of neurons and surrounding astrocytes, without shrinkage or swelling.</s><s sid='272'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The immunohistochemical findings from the FJB staining assay were consistent with the ultrastructural results.</s><s sid='273'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> The total number of FJB-positive cells in the cerebral cortex showed a significant reduction after pinocembrin treatment, indicating that pinocembrin might be effective in decreasing neurodegeneration and improving cerebral histomorphological outcomes.</s><s sid='274'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> As a result of the current study on <italic>in vivo </italic>cognitive function, neuronal ultrastructural investigation and neuronal degeneration detection, pinocembrin has been shown to be potentially beneficial for the treatment of AD.</s><s sid='275'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Therefore, the underlying mechanism of its actual therapeutic value has been explored and is discussed as below.</s></p><p><s sid='276'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Oxidative stress plays a critical role in AD pathogenesis.</s><s sid='277'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> ROS production can be largely catalyzed by transition metals, such as copper [<xref rid='B48' ref-type='bibr'>48</xref>,<xref rid='B49' ref-type='bibr'>49</xref>].</s><s sid='278'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The association of copper and Aβ toxicity is mainly suggested in three aspects: (1) the effect on cell viability correlated with Aβ; (2) Aβ-induced neurotoxicity relevant to oxidative stress indicated by ROS production; and (3) the effect of copper in Aβ aggregation.</s><s sid='279'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Here, we detected that copper increased ROS generation by about a 3.3-fold increase, in accordance with Aβ peptide secretion and decrease of cell viability.</s><s sid='280'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, pinocembrin did not affect Aβ<sub>1-42 </sub>secretion.</s><s sid='281'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> It modestly and non-significantly scavenged ROS generation.</s><s sid='282'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Pinocembrin belongs to the flavonoids, which are thought to be effective in quenching free radicals [<xref rid='B50' ref-type='bibr'>50</xref>].</s><s sid='283'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Although it showed the antioxidative activities in scavenging ROS production and decreasing some of oxidant enzyme activity in reducing ischemic injury [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B25' ref-type='bibr'>25</xref>], pinocembrin did not provide sufficient antioxidant effect through scavenging ROS generation against Aβ-mediated neurotoxicity stimulated by copper.</s><s sid='284'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our present data suggest that pinocembrin may act synergistically with other mechanisms for the treatment of AD.</s></p><p><s sid='285'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Evidence has indicated that APP localizes not only to the plasma membrane, but also to the mitochondrial membrane, trans-Golgi network, endoplasmic reticulum, and lysosomal membrane [<xref rid='B51' ref-type='bibr'>51</xref>-<xref rid='B53' ref-type='bibr'>53</xref>].</s><s sid='286'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Therefore, two potential pathways may underlie the neurotoxicity of intraneuronal Aβ: (1) Aβ secreted into extracellular space is subsequently taken up by neurons at the neuronal cell surface, and causes neuronal dysfunction mainly via RAGE-dependent pathway; (2) Aβ produced intracellularly remains within the neuron, and promotes toxicity to various cytoplasmic organoids [<xref rid='B54' ref-type='bibr'>54</xref>].</s><s sid='287'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> According to the possible neurotoxic pathways of Aβ, our following explanations for the therapeutic mechanism of pinocembrin consist of the above two aspects.</s></p><p><s sid='288'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>RAGE is a potential therapeutic target in Aβ-induced processes in AD neuropathology.</s><s sid='289'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Neuronal RAGE is highly overexpressed in AD patients, and has capacity to bind various forms of Aβ at the neuronal cell surface [<xref rid='B12' ref-type='bibr'>12</xref>,<xref rid='B55' ref-type='bibr'>55</xref>,<xref rid='B56' ref-type='bibr'>56</xref>].</s><s sid='290'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The neurotoxic response to Aβ-RAGE correlates with activation the three subfamilies of MAPKs, p38MAPK, SAPK/JNK, and extracellular signal-regulated kinase (ERK1/2, p44/42 MAPK), and NFκB transduction.</s><s sid='291'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Among these toxic transductions, p38-MK2-HSP27 and JNK/c-Jun have been shown to play important roles in Aβ/RAGE-induced synaptic dysfunction.</s><s sid='292'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These two pathways may be triggered by RAGE/Aβ as downstream signaling cascades that contribute to the early phases of AD [<xref rid='B57' ref-type='bibr'>57</xref>-<xref rid='B59' ref-type='bibr'>59</xref>].</s></p><p><s sid='293'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Based on our <italic>in vivo </italic>and <italic>in vitro </italic>studies, one of the explanations for the molecular mechanism of pinocembrin is the regulation of Aβ/RAGE-mediated pathways (Figure <xref rid='F10' ref-type='fig'>10</xref>).</s><s sid='294'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Neuronal RAGE transcripts and protein expression were significantly upregulated in Aβ-mediated neurotoxicity models, which is in good agreement with previous AD animal models [<xref rid='B56' ref-type='bibr'>56</xref>,<xref rid='B59' ref-type='bibr'>59</xref>].</s><s sid='295'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As a consequence of RAGE overexpression and Aβ-RAGE activation, p38MAPK-MK2-HSP27 and SAPK/JNK-c-Jun cascades were phosphorylated and activated in the copper-treated APPsw overexpressing cell system.</s><s sid='296'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin significantly inhibited the upregulation of RAGE transcripts in accordance with its protein expression both <italic>in vivo </italic>and <italic>in vitro</italic>.</s><s sid='297'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In the Aβ<sub>1-42</sub>-treated RAGE overexpressing cell system, an evaluating <italic>in vitro </italic>model with a strong response region of wild-type human RAGE promoter for inducing RAGE expression in which Aβ acts as a stimulator when supplemented in culture medium, pinocembrin showed a direct inhibitory effect on RAGE expression.</s><s sid='298'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Thereby we confirmed that pinocembrin was effective in inhibiting the overexpression of RAGE against Aβ-mediated toxicity, and speculate that pinocembrin may affect RAGE transcription by interacting with the gene promoter, affecting the regulatory factors of the gene promoter, or stabilizing mRNAs in the mRNA processing or post-transcriptional regulation levels.</s><s sid='299'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our results further revealed that pinocembrin markedly inhibited the activation of p38MAPK-MK2-HSP27 and SAPK/JNK-c-Jun pathways, accompanied by a weak and apparently ineffective inhibitory effect on ERK1/2 activation.</s><s sid='300'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> These inhibitory effects of pinocembrin may be secondary to the lowering of the Aβ-RAGE interaction.</s></p><fig id='F10' position='float'><label>Figure 10</label><caption><p><bold>Schematic diagram of the neuroprotective pathways of pinocembrin on amyloid-β peptide (Aβ)-induced neurotoxicity</bold>.</p></caption><graphic xlink:href='1741-7015-10-105-10'></graphic></fig><p><s sid='301'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>NFκB activation is also a neurotoxic signaling event subsequent to Aβ-RAGE activation.</s><s sid='302'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> RAGE-mediated activation of NFκB by Aβ in the brain could lead either to comprehensive inflammation or to signaling that could result in apoptosis.</s><s sid='303'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In our <italic>in vitro </italic>study, pinocembrin significantly hampered NFκB p65 nuclear translocation and inhibited inflammatory factor release.</s><s sid='304'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Based on the present data and previous reports [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B60' ref-type='bibr'>60</xref>,<xref rid='B61' ref-type='bibr'>61</xref>], the anti-inflammatory effect of pinocembrin demonstrated here might be either a direct effect independent of Aβ toxicity or a secondary effect subsequent to the Aβ-RAGE interaction (Figure <xref rid='F10' ref-type='fig'>10</xref>).</s></p><p><s sid='305'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1>Another explanation for pinocembrin promoting cognitive function and preserving neuronal ultrastructure against Aβ-induced toxicity is that pinocembrin protected mitochondria and regulated mitochondrion-mediated apoptosis (Figure <xref rid='F10' ref-type='fig'>10</xref>).</s><s sid='306'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Mitochondria play a pivotal role in apoptosis signaling pathways.</s><s sid='307'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Loss of MMP contributes to cell death by reducing ATP production, increasing production of ROS, and enhancing release of deadly signal molecules from the intermembrane space, thereby leading to caspase-dependent toxicity and downstream apoptotic signaling [<xref rid='B62' ref-type='bibr'>62</xref>].</s><s sid='308'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> As discussed above, Aβ also localizes to the mitochondrial membrane and has a direct toxicity to mitochondrial function.</s><s sid='309'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Further, activation of MAPKs signaling pathways in response to a variety of stressors such as oxidative stress, also leads to neuronal apoptosis via the mitochondria-dependent pathway [<xref rid='B63' ref-type='bibr'>63</xref>].</s><s sid='310'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> According to our study, a loss of MMP and a special oxidation of mitochondria were apparent in APPsw cells in the presence of copper, coincidence with intracellular ROS overgeneration and MAPKs activation.</s><s sid='311'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> As previous studies have reported, pinocembrin showed a direct protective effect on mitochondria [<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B27' ref-type='bibr'>27</xref>], and we also observed that pinocembrin alleviated mitochondrial dysfunction through improving mitochondrial membrane potential and protecting mitochondria from oxidative stress.</s></p><p><s sid='312'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Of the apoptotic molecular makers during the mitochondrion-dependent pathway, Bcl-2, localized to mitochondria, may prevent apoptotic events by lowering the amount of free Ca<sup>2+ </sup>and increasing the tolerance of mitochondria to high calcium loads [<xref rid='B64' ref-type='bibr'>64</xref>].</s><s sid='313'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Once mitochondrial membrane permeabilization is induced, cytochrome <italic>c </italic>is released, forming an oligomeric complex with dATP and Apaf-1 [<xref rid='B65' ref-type='bibr'>65</xref>], accompanied by recruitment of procaspase 9 and its activation.</s><s sid='314'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In this study, cytochrome <italic>c</italic>, Bcl-2 and caspase 3 and caspase 9 were all were changed in APPsw cells in the presence of copper.</s><s sid='315'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Pinocembrin inhibited mitochondrion-dependent apoptosis.</s><s sid='316'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Nuclear condensation was also attenuated by pinocembrin treatment.</s></p><p><s sid='317'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Additionally, there are other molecular components involved in apoptosis from different upstream signaling pathways.</s><s sid='318'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The release of cytochrome <italic>c </italic>is tightly linked to the presence and activation of JNK, and the JNK mediated cytochrome <italic>c </italic>release contributing to caspase 3 activation and apoptosis onset [<xref rid='B66' ref-type='bibr'>66</xref>,<xref rid='B67' ref-type='bibr'>67</xref>].</s><s sid='319'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In addition, HSP27 regulates apoptosis by inhibiting the release of cytochrome <italic>c </italic>and preventing the activation of caspase 3 [<xref rid='B68' ref-type='bibr'>68</xref>].</s><s sid='320'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Combined with this evidence, pinocembrin is also illustrated to modulate apoptosis synergistically with the inactivation of SAPK/JNK-c-Jun pathway.</s></p></sec><sec sec-type='conclusions'><title>Conclusions</title><p><s sid='321'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>With the experimental design and methodology used in the present study, we investigated the therapeutic value of pinocembrin in cognitive function and neuronal protection against Aβ-induced toxicity.</s><s sid='322'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Furthermore, we explored the therapeutic targets for the efficacy of pinocembrin, and demonstrated the underlying mechanisms of pinocembrin through inhibiting RAGE-dependent signaling pathway and regulating mitochondrion-mediated apoptosis.</s><s sid='323'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In summary, pinocembrin appears to be a promising candidate for the prevention and therapy of Alzheimer's disease.</s></p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>RL participated in the design of the study, and carried out the animal experiments as well as the TEM analysis and drafted the manuscript. C-xW performed RAGE expression analyses and FJB staining assay. RL, DZ and ST carried out cell culture and gene transfection experiments. FY and LZ evaluated and analyzed the MAPK signal pathways, NFκB activation and apoptotic pathway transduction. T-tZ carried out mitochondrial assays. RL, DZ and T-tZ performed the statistical analysis. G-hD conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type='uri' xlink:href='http://www.biomedcentral.com/1741-7015/10/105/prepub'>http://www.biomedcentral.com/1741-7015/10/105/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>This work was supported by Major Scientific and Technological Special Project for 'Significant New Drugs Creation' (no. 2009ZX09302-003, 2009ZX09102-034), National Natural Science Foundation of China (no. 81102830) and Central Public Scientific Research Institution Fundamental Project (2011CHX01). We especially thank Professor Shou-zhi Wang, Northeast Agricultural University, and Professor Ying Peng, Chinese Academy of Medical Sciences, for guidance in the statistical analysis, and critical reading and writing assistance.</p></sec><ref-list><ref id='B1'><mixed-citation publication-type='journal'><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Normal and abnormal biology of the beta-amyloid precursor protein</article-title><source>Annu Rev Neurosci</source><year>1994</year><volume>17</volume><fpage>489</fpage><lpage>517</lpage><pub-id pub-id-type='doi'>10.1146/annurev.ne.17.030194.002421</pub-id><pub-id pub-id-type='pmid'>8210185</pub-id></mixed-citation></ref><ref id='B2'><mixed-citation publication-type='journal'><name><surname>Rohn</surname><given-names>TT</given-names></name><name><surname>Head</surname><given-names>E</given-names></name><name><surname>Su</surname><given-names>JH</given-names></name><name><surname>Anderson</surname><given-names>AJ</given-names></name><name><surname>Bahr</surname><given-names>BA</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><article-title>Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease</article-title><source>Am J Pathol</source><year>2001</year><volume>158</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='doi'>10.1016/S0002-9440(10)63957-0</pub-id><pub-id pub-id-type='pmid'>11141492</pub-id></mixed-citation></ref><ref id='B3'><mixed-citation publication-type='journal'><name><surname>Su</surname><given-names>JH</given-names></name><name><surname>Nichol</surname><given-names>KE</given-names></name><name><surname>Sitch</surname><given-names>T</given-names></name><name><surname>Sheu</surname><given-names>P</given-names></name><name><surname>Chubb</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Tomaselli</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>RC</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><article-title>DNA damage and activated caspase-3 expression in neurons and astrocytes: evidence for apoptosis in frontotemporal dementia</article-title><source>Exp Neurol</source><year>2000</year><volume>163</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type='doi'>10.1006/exnr.2000.7340</pub-id><pub-id pub-id-type='pmid'>10785439</pub-id></mixed-citation></ref><ref id='B4'><mixed-citation publication-type='journal'><name><surname>Zilka</surname><given-names>N</given-names></name><name><surname>Ferencik</surname><given-names>M</given-names></name><name><surname>Hulin</surname><given-names>I</given-names></name><article-title>Neuroinflammation in Alzheimer's disease: protector or promoter?</article-title><source>Bratisl Lek Listy</source><year>2006</year><volume>107</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type='pmid'>17262990</pub-id></mixed-citation></ref><ref id='B5'><mixed-citation publication-type='journal'><name><surname>Eckert</surname><given-names>A</given-names></name><name><surname>Keil</surname><given-names>U</given-names></name><name><surname>Marques</surname><given-names>CA</given-names></name><name><surname>Bonert</surname><given-names>A</given-names></name><name><surname>Frey</surname><given-names>C</given-names></name><name><surname>Schussel</surname><given-names>K</given-names></name><name><surname>Muller</surname><given-names>WE</given-names></name><article-title>Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease</article-title><source>Biochem Pharmacol</source><year>2003</year><volume>66</volume><fpage>1627</fpage><lpage>1634</lpage><pub-id pub-id-type='doi'>10.1016/S0006-2952(03)00534-3</pub-id><pub-id pub-id-type='pmid'>14555243</pub-id></mixed-citation></ref><ref id='B6'><mixed-citation publication-type='journal'><name><surname>Parks</surname><given-names>JK</given-names></name><name><surname>Smith</surname><given-names>TS</given-names></name><name><surname>Trimmer</surname><given-names>PA</given-names></name><name><surname>Bennett</surname><given-names>JP</given-names><suffix>Jr</suffix></name><name><surname>Parker</surname><given-names>WD</given-names><suffix>Jr</suffix></name><article-title>Neurotoxic Aβ peptides increase oxidative stress <italic>in vivo </italic>through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition <italic>in vitro</italic></article-title><source>J Neurochem</source><year>2001</year><volume>76</volume><fpage>1050</fpage><lpage>1056</lpage><pub-id pub-id-type='doi'>10.1046/j.1471-4159.2001.00112.x</pub-id><pub-id pub-id-type='pmid'>11181824</pub-id></mixed-citation></ref><ref id='B7'><mixed-citation publication-type='journal'><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Roher</surname><given-names>A</given-names></name><name><surname>Slattery</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Nagashima</surname><given-names>M</given-names></name><name><surname>Morser</surname><given-names>J</given-names></name><name><surname>Migheli</surname><given-names>A</given-names></name><name><surname>Nawroth</surname><given-names>P</given-names></name><name><surname>Stern</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><article-title>RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease</article-title><source>Nature</source><year>1996</year><volume>382</volume><fpage>685</fpage><lpage>691</lpage><pub-id pub-id-type='doi'>10.1038/382685a0</pub-id><pub-id pub-id-type='pmid'>8751438</pub-id></mixed-citation></ref><ref id='B8'><mixed-citation publication-type='journal'><name><surname>Auld</surname><given-names>DS</given-names></name><name><surname>Kornecook</surname><given-names>TJ</given-names></name><name><surname>Bastianetto</surname><given-names>S</given-names></name><name><surname>Quirion</surname><given-names>R</given-names></name><article-title>Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies</article-title><source>Prog Neurobiol</source><year>2002</year><volume>68</volume><fpage>209</fpage><lpage>245</lpage><pub-id pub-id-type='doi'>10.1016/S0301-0082(02)00079-5</pub-id><pub-id pub-id-type='pmid'>12450488</pub-id></mixed-citation></ref><ref id='B9'><mixed-citation publication-type='journal'><name><surname>Bartus</surname><given-names>RT</given-names></name><name><surname>Dean</surname><given-names>RL</given-names></name><article-title>Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps</article-title><source>Psychopharmacology (Berl)</source><year>2009</year><volume>202</volume><fpage>15</fpage><lpage>36</lpage><pub-id pub-id-type='doi'>10.1007/s00213-008-1365-7</pub-id><pub-id pub-id-type='pmid'>19011839</pub-id></mixed-citation></ref><ref id='B10'><mixed-citation publication-type='journal'><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Alzheimer's disease is a synaptic failure</article-title><source>Science</source><year>2002</year><volume>298</volume><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type='doi'>10.1126/science.1074069</pub-id><pub-id pub-id-type='pmid'>12399581</pub-id></mixed-citation></ref><ref id='B11'><mixed-citation publication-type='journal'><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Kuppusamy</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Godman</surname><given-names>GC</given-names></name><name><surname>Nawroth</surname><given-names>P</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Stern</surname><given-names>D</given-names></name><article-title>Nonenzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of Aβ</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>693</fpage><lpage>699</lpage><pub-id pub-id-type='doi'>10.1038/nm0795-693</pub-id><pub-id pub-id-type='pmid'>7585153</pub-id></mixed-citation></ref><ref id='B12'><mixed-citation publication-type='journal'><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Brachova</surname><given-names>L</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><article-title>Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism</article-title><source>Exp Neurol</source><year>2001</year><volume>171</volume><fpage>29</fpage><lpage>45</lpage><pub-id pub-id-type='doi'>10.1006/exnr.2001.7732</pub-id><pub-id pub-id-type='pmid'>11520119</pub-id></mixed-citation></ref><ref id='B13'><mixed-citation publication-type='journal'><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Bierhaus</surname><given-names>A</given-names></name><name><surname>Nawroth</surname><given-names>PP</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name><article-title>RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation?</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>16</volume><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type='pmid'>19387116</pub-id></mixed-citation></ref><ref id='B14'><mixed-citation publication-type='journal'><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name><article-title>The biology of the receptor for advanced glycation end products and its ligands</article-title><source>Biochim Biophys Acta</source><year>2000</year><volume>1498</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type='doi'>10.1016/S0167-4889(00)00087-2</pub-id><pub-id pub-id-type='pmid'>11108954</pub-id></mixed-citation></ref><ref id='B15'><mixed-citation publication-type='journal'><name><surname>Onyango</surname><given-names>IG</given-names></name><name><surname>Tuttle</surname><given-names>JB</given-names></name><name><surname>Bennett</surname><given-names>JP</given-names><suffix>Jr</suffix></name><article-title>Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE)</article-title><source>Mol Cell Neurosci</source><year>2005</year><volume>29</volume><fpage>333</fpage><lpage>343</lpage><pub-id pub-id-type='doi'>10.1016/j.mcn.2005.02.012</pub-id><pub-id pub-id-type='pmid'>15911356</pub-id></mixed-citation></ref><ref id='B16'><mixed-citation publication-type='journal'><name><surname>Mucke</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>GQ</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><name><surname>Rockenstein</surname><given-names>EM</given-names></name><name><surname>Abraham</surname><given-names>CR</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>Astroglial expression of human α(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice</article-title><source>Am J Pathol</source><year>2000</year><volume>157</volume><fpage>2003</fpage><lpage>2010</lpage><pub-id pub-id-type='doi'>10.1016/S0002-9440(10)64839-0</pub-id><pub-id pub-id-type='pmid'>11106573</pub-id></mixed-citation></ref><ref id='B17'><mixed-citation publication-type='journal'><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>HP</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Trinchese</surname><given-names>F</given-names></name><name><surname>Puzzo</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Hegde</surname><given-names>A</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Stern</surname><given-names>A</given-names></name><name><surname>Luddy</surname><given-names>JS</given-names></name><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Roher</surname><given-names>A</given-names></name><name><surname>Buttini</surname><given-names>M</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Kindy</surname><given-names>M</given-names></name><name><surname>Hyslop</surname><given-names>PA</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name><name><surname>Du Yan</surname><given-names>SS</given-names></name><article-title>RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>4096</fpage><lpage>4105</lpage><pub-id pub-id-type='doi'>10.1038/sj.emboj.7600415</pub-id><pub-id pub-id-type='pmid'>15457210</pub-id></mixed-citation></ref><ref id='B18'><mixed-citation publication-type='journal'><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>RJ</given-names></name><name><surname>Morton</surname><given-names>AJ</given-names></name><name><surname>Nicholson</surname><given-names>LF</given-names></name><article-title>RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats</article-title><source>Brain Res</source><year>2003</year><volume>966</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type='doi'>10.1016/S0006-8993(02)04149-5</pub-id><pub-id pub-id-type='pmid'>12618340</pub-id></mixed-citation></ref><ref id='B19'><mixed-citation publication-type='journal'><name><surname>Rong</surname><given-names>LL</given-names></name><name><surname>Gooch</surname><given-names>C</given-names></name><name><surname>Szabolcs</surname><given-names>M</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name><name><surname>Lalla</surname><given-names>E</given-names></name><name><surname>Hays</surname><given-names>AP</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Yan</surname><given-names>SS</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><article-title>RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair</article-title><source>Restor Neurol Neurosci</source><year>2005</year><volume>23</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type='pmid'>16477098</pub-id></mixed-citation></ref><ref id='B20'><mixed-citation publication-type='journal'><name><surname>Kumazawa</surname><given-names>S</given-names></name><name><surname>Shimoi</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Hamasaka</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><article-title>Identification of metabolites in plasma and urine of Uruguayan propolis-treated rats</article-title><source>J Agric Food Chem</source><year>2004</year><volume>52</volume><fpage>3083</fpage><lpage>3088</lpage><pub-id pub-id-type='doi'>10.1021/jf0353234</pub-id><pub-id pub-id-type='pmid'>15137857</pub-id></mixed-citation></ref><ref id='B21'><mixed-citation publication-type='journal'><name><surname>Yang</surname><given-names>ZH</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Mei</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>XB</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><article-title>Uptake characteristics of pinocembrin and its effect on p-glycoprotein at the blood-brain barrier in in vitro cell experiments</article-title><source>J Asian Nat Prod Res</source><year>2012</year><volume>14</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type='doi'>10.1080/10286020.2011.620393</pub-id><pub-id pub-id-type='pmid'>22263589</pub-id></mixed-citation></ref><ref id='B22'><mixed-citation publication-type='journal'><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>ZH</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><article-title>Pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both <italic>in vivo </italic>and <italic>in vitro</italic></article-title><source>Brain Res</source><year>2008</year><volume>1216</volume><fpage>104</fpage><lpage>115</lpage><pub-id pub-id-type='pmid'>18495093</pub-id></mixed-citation></ref><ref id='B23'><mixed-citation publication-type='journal'><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>WC</given-names></name><name><surname>Liu</surname><given-names>QS</given-names></name><name><surname>Hu</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>GT</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><article-title>Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio</article-title><source>Eur J Pharmacol</source><year>2008</year><volume>591</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type='doi'>10.1016/j.ejphar.2008.06.071</pub-id><pub-id pub-id-type='pmid'>18625218</pub-id></mixed-citation></ref><ref id='B24'><mixed-citation publication-type='journal'><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>SY</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><article-title>Acute neurovascular unit protective action of pinocembrin against permanent cerebral ischemia in rats</article-title><source>J Asian Nat Prod Res</source><year>2008</year><volume>10</volume><fpage>551</fpage><lpage>558</lpage><pub-id pub-id-type='doi'>10.1080/10286020801966955</pub-id><pub-id pub-id-type='pmid'>18470808</pub-id></mixed-citation></ref><ref id='B25'><mixed-citation publication-type='journal'><name><surname>Shi</surname><given-names>LL</given-names></name><name><surname>Chen</surname><given-names>BN</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>HA</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><article-title>The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats</article-title><source>Life Sci</source><year>2011</year><volume>88</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type='doi'>10.1016/j.lfs.2011.01.011</pub-id><pub-id pub-id-type='pmid'>21262238</pub-id></mixed-citation></ref><ref id='B26'><mixed-citation publication-type='journal'><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Xuan</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>G</given-names></name><article-title>Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats</article-title><source>Brain Res</source><year>2011</year><volume>1391</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type='pmid'>21435338</pub-id></mixed-citation></ref><ref id='B27'><mixed-citation publication-type='journal'><name><surname>Guang</surname><given-names>HM</given-names></name><name><surname>Du</surname><given-names>GH</given-names></name><article-title>Protections of pinocembrin on brain mitochondria contribute to cognitive improvement in chronic cerebral hypoperfused rats</article-title><source>Eur J Pharmacol</source><year>2006</year><volume>542</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type='doi'>10.1016/j.ejphar.2006.04.054</pub-id><pub-id pub-id-type='pmid'>16806158</pub-id></mixed-citation></ref><ref id='B28'><mixed-citation publication-type='journal'><name><surname>Morris</surname><given-names>R</given-names></name><article-title>Developments of a water-maze procedure for studying spatial learning in the rat</article-title><source>J Neurosci Methods</source><year>1984</year><volume>11</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type='doi'>10.1016/0165-0270(84)90007-4</pub-id><pub-id pub-id-type='pmid'>6471907</pub-id></mixed-citation></ref><ref id='B29'><mixed-citation publication-type='journal'><name><surname>Schmued</surname><given-names>LC</given-names></name><name><surname>Hopkins</surname><given-names>KJ</given-names></name><article-title>Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration</article-title><source>Brain Res</source><year>2000</year><volume>874</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type='doi'>10.1016/S0006-8993(00)02513-0</pub-id><pub-id pub-id-type='pmid'>10960596</pub-id></mixed-citation></ref><ref id='B30'><mixed-citation publication-type='journal'><name><surname>Candelario-Jalil</surname><given-names>E</given-names></name><name><surname>Alvarez</surname><given-names>D</given-names></name><name><surname>Merino</surname><given-names>N</given-names></name><name><surname>Leon</surname><given-names>OS</given-names></name><article-title>Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils</article-title><source>Neurosci Res</source><year>2003</year><volume>47</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type='doi'>10.1016/S0168-0102(03)00184-6</pub-id><pub-id pub-id-type='pmid'>14512150</pub-id></mixed-citation></ref><ref id='B31'><mixed-citation publication-type='journal'><name><surname>Rüster</surname><given-names>C</given-names></name><name><surname>Bondeva</surname><given-names>T</given-names></name><name><surname>Franke</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>G</given-names></name><article-title>Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors</article-title><source>Am J Nephrol</source><year>2009</year><volume>29</volume><fpage>538</fpage><lpage>550</lpage><pub-id pub-id-type='doi'>10.1159/000191467</pub-id><pub-id pub-id-type='pmid'>19129693</pub-id></mixed-citation></ref><ref id='B32'><mixed-citation publication-type='journal'><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Lan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>G</given-names></name><article-title>Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevents copper-mediated toxicity in β-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells</article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>2084</fpage><lpage>2096</lpage><pub-id pub-id-type='doi'>10.3390/molecules16032084</pub-id><pub-id pub-id-type='pmid'>21368720</pub-id></mixed-citation></ref><ref id='B33'><mixed-citation publication-type='journal'><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Enokido</surname><given-names>Y</given-names></name><name><surname>Aoshima</surname><given-names>H</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><article-title>Changes in mitochondrialmembrane potential during oxidative stress-Induced apoptosis in PC12 cells</article-title><source>Neurosci Res</source><year>1997</year><volume>50</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type='doi'>10.1002/(SICI)1097-4547(19971101)50:3&lt;413::AID-JNR7&gt;3.0.CO;2-L</pub-id></mixed-citation></ref><ref id='B34'><mixed-citation publication-type='journal'><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Thiels</surname><given-names>E</given-names></name><name><surname>Chu</surname><given-names>CT</given-names></name><name><surname>Wu</surname><given-names>GY</given-names></name><name><surname>Oury</surname><given-names>TD</given-names></name><name><surname>Klann</surname><given-names>E</given-names></name><article-title>Hippocampal long-term potentiation, memory, and longevity in mice that overexpress mitochondrial superoxide dismutase</article-title><source>Neurobiol Learn Mem</source><year>2007</year><volume>87</volume><fpage>372</fpage><lpage>384</lpage><pub-id pub-id-type='doi'>10.1016/j.nlm.2006.10.003</pub-id><pub-id pub-id-type='pmid'>17129739</pub-id></mixed-citation></ref><ref id='B35'><mixed-citation publication-type='journal'><name><surname>Trask</surname><given-names>OJ</given-names></name><name><surname>Nickischer</surname><given-names>D</given-names></name><name><surname>Burton</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>RG</given-names></name><name><surname>Kandasamy</surname><given-names>RA</given-names></name><name><surname>Johnston</surname><given-names>PA</given-names></name><name><surname>Johnston</surname><given-names>PA</given-names></name><article-title>High-throughput automated confocal microscopy imaging screen of a kinase-focused library to identify p38 mitogen-activated protein kinase inhibitors using the GE InCell 3000 analyzer</article-title><source>Methods Mol Biol</source><year>2009</year><volume>565</volume><fpage>159</fpage><lpage>186</lpage><pub-id pub-id-type='doi'>10.1007/978-1-60327-258-2_8</pub-id><pub-id pub-id-type='pmid'>19551362</pub-id></mixed-citation></ref><ref id='B36'><mixed-citation publication-type='journal'><name><surname>Bertelsen</surname><given-names>M</given-names></name><article-title>Multiplex analysis of inflammatory signaling pathways using a high-content imaging system</article-title><source>Methods Enzymol</source><year>2006</year><volume>414</volume><fpage>348</fpage><lpage>363</lpage><pub-id pub-id-type='pmid'>17110202</pub-id></mixed-citation></ref><ref id='B37'><mixed-citation publication-type='journal'><name><surname>Butterfield</surname><given-names>DA</given-names></name><name><surname>Reed</surname><given-names>T</given-names></name><name><surname>Newman</surname><given-names>SF</given-names></name><name><surname>Sultan</surname><given-names>R</given-names></name><article-title>Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment</article-title><source>Free Radic Biol Med</source><year>2007</year><volume>43</volume><fpage>658</fpage><lpage>677</lpage><pub-id pub-id-type='doi'>10.1016/j.freeradbiomed.2007.05.037</pub-id><pub-id pub-id-type='pmid'>17664130</pub-id></mixed-citation></ref><ref id='B38'><mixed-citation publication-type='journal'><name><surname>Nitta</surname><given-names>A</given-names></name><name><surname>Itoh</surname><given-names>A</given-names></name><name><surname>Hasegawa</surname><given-names>T</given-names></name><name><surname>Nabeshima</surname><given-names>T</given-names></name><article-title>β-Amyloid protein-induced Alzheimer's disease animal model</article-title><source>Neurosci Lett</source><year>1994</year><volume>170</volume><fpage>63</fpage><lpage>66</lpage><pub-id pub-id-type='doi'>10.1016/0304-3940(94)90239-9</pub-id><pub-id pub-id-type='pmid'>8086012</pub-id></mixed-citation></ref><ref id='B39'><mixed-citation publication-type='journal'><name><surname>Hoshi</surname><given-names>M</given-names></name><name><surname>Takashima</surname><given-names>A</given-names></name><name><surname>Murayama</surname><given-names>M</given-names></name><name><surname>Yasutake</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Ishiguro</surname><given-names>K</given-names></name><name><surname>Hoshino</surname><given-names>T</given-names></name><name><surname>Imahori</surname><given-names>K</given-names></name><article-title>Nontoxic amyloid β peptide 1-42 suppresses acetylcholine synthesis</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>2038</fpage><lpage>2041</lpage><pub-id pub-id-type='doi'>10.1074/jbc.272.4.2038</pub-id><pub-id pub-id-type='pmid'>8999897</pub-id></mixed-citation></ref><ref id='B40'><mixed-citation publication-type='journal'><name><surname>Kar</surname><given-names>S</given-names></name><name><surname>Issa</surname><given-names>AM</given-names></name><name><surname>Seto</surname><given-names>D</given-names></name><name><surname>Auld</surname><given-names>DS</given-names></name><name><surname>Collier</surname><given-names>B</given-names></name><name><surname>Quirion</surname><given-names>R</given-names></name><article-title>Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices</article-title><source>J Neurochem</source><year>1998</year><volume>70</volume><fpage>2179</fpage><lpage>2187</lpage><pub-id pub-id-type='pmid'>9572306</pub-id></mixed-citation></ref><ref id='B41'><mixed-citation publication-type='journal'><name><surname>Sigurdsson</surname><given-names>EM</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Dong</surname><given-names>XW</given-names></name><name><surname>Hejna</surname><given-names>MJ</given-names></name><name><surname>Lorens</surname><given-names>SA</given-names></name><article-title>Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects</article-title><source>Neurobiol Aging</source><year>1997</year><volume>18</volume><fpage>591</fpage><lpage>608</lpage><pub-id pub-id-type='doi'>10.1016/S0197-4580(97)00154-1</pub-id><pub-id pub-id-type='pmid'>9461057</pub-id></mixed-citation></ref><ref id='B42'><mixed-citation publication-type='journal'><name><surname>Pavia</surname><given-names>J</given-names></name><name><surname>Alberch</surname><given-names>J</given-names></name><name><surname>Alverez</surname><given-names>I</given-names></name><name><surname>Toledano</surname><given-names>A</given-names></name><name><surname>de Ceballos</surname><given-names>ML</given-names></name><article-title>Repeated intracerebroventricular administration of β-amyloid 25-35 to rats decreases muscarinic receptors in cerebral cortex</article-title><source>Neurosci Lett</source><year>2000</year><volume>278</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type='doi'>10.1016/S0304-3940(99)00900-3</pub-id><pub-id pub-id-type='pmid'>10643803</pub-id></mixed-citation></ref><ref id='B43'><mixed-citation publication-type='journal'><name><surname>Nakdook</surname><given-names>W</given-names></name><name><surname>Khongsombat</surname><given-names>O</given-names></name><name><surname>Taepavarapruk</surname><given-names>P</given-names></name><name><surname>Taepavarapruk</surname><given-names>N</given-names></name><name><surname>Ingkaninan</surname><given-names>K</given-names></name><article-title>The effects of Tabernaemontana divaricata root extract on amyloid beta-peptide 25-35 peptides induced cognitive deficits in mice</article-title><source>J Ethnopharmacol</source><year>2010</year><volume>130</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type='doi'>10.1016/j.jep.2010.04.027</pub-id><pub-id pub-id-type='pmid'>20435125</pub-id></mixed-citation></ref><ref id='B44'><mixed-citation publication-type='journal'><name><surname>Rovira</surname><given-names>C</given-names></name><name><surname>Arbez</surname><given-names>N</given-names></name><name><surname>Mariani</surname><given-names>J</given-names></name><article-title>Aβ(25-35) and Aβ(1-40) act on different calcium channels in CA1 hippocampal neurons</article-title><source>Biochem Biophys Res Commun</source><year>2002</year><volume>296</volume><fpage>1317</fpage><lpage>1321</lpage><pub-id pub-id-type='doi'>10.1016/S0006-291X(02)02072-7</pub-id><pub-id pub-id-type='pmid'>12207918</pub-id></mixed-citation></ref><ref id='B45'><mixed-citation publication-type='journal'><name><surname>Gruden</surname><given-names>MA</given-names></name><name><surname>Davidova</surname><given-names>TB</given-names></name><name><surname>Malisauskas</surname><given-names>M</given-names></name><name><surname>Sewell</surname><given-names>RD</given-names></name><name><surname>Voskresenskaya</surname><given-names>NI</given-names></name><name><surname>Wilhelm</surname><given-names>K</given-names></name><name><surname>Elistratova</surname><given-names>EI</given-names></name><name><surname>Sherstnev</surname><given-names>VV</given-names></name><name><surname>Morozova-Roche</surname><given-names>LA</given-names></name><article-title>Differential neuroimmune markers to the onset of Alzheimer's disease neuro-degeneration and dementia: autoantibodies to Aβ(25-35) oligomers. S100b and neurotransmitters</article-title><source>J Neuroimmunol</source><year>2007</year><volume>186</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type='doi'>10.1016/j.jneuroim.2007.03.023</pub-id><pub-id pub-id-type='pmid'>17477976</pub-id></mixed-citation></ref><ref id='B46'><mixed-citation publication-type='journal'><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><article-title>Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells</article-title><source>Neurochem Int</source><year>2010</year><volume>57</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type='doi'>10.1016/j.neuint.2010.06.021</pub-id><pub-id pub-id-type='pmid'>20615444</pub-id></mixed-citation></ref><ref id='B47'><mixed-citation publication-type='journal'><name><surname>Quintana</surname><given-names>C</given-names></name><name><surname>Lancin</surname><given-names>M</given-names></name><name><surname>Marhic</surname><given-names>C</given-names></name><name><surname>Pérez</surname><given-names>M</given-names></name><name><surname>Martin-Benito</surname><given-names>J</given-names></name><name><surname>Avila</surname><given-names>J</given-names></name><name><surname>Carrascosa</surname><given-names>JL</given-names></name><article-title>Initial studies with high resolution TEM and electron energy loss spectroscopy studies of ferritin cores extracted from brains of patients with progressive supranuclear palsy and Alzheimer disease</article-title><source>Cell Mol Biol</source><year>2000</year><volume>46</volume><fpage>807</fpage><lpage>820</lpage><pub-id pub-id-type='pmid'>10875442</pub-id></mixed-citation></ref><ref id='B48'><mixed-citation publication-type='journal'><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>Scheuermann</surname><given-names>S</given-names></name><name><surname>Schlicksupp</surname><given-names>A</given-names></name><name><surname>Simons</surname><given-names>A</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name><name><surname>Kemmling</surname><given-names>A</given-names></name><name><surname>Oehler</surname><given-names>C</given-names></name><name><surname>Cappai</surname><given-names>R</given-names></name><name><surname>Pipkorn</surname><given-names>R</given-names></name><name><surname>Bayer</surname><given-names>TA</given-names></name><article-title>Possible mechanisms of APP-mediated oxidative stress in Alzheimer's disease</article-title><source>Free Radic Biol Med</source><year>2002</year><volume>33</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type='doi'>10.1016/S0891-5849(02)00806-7</pub-id><pub-id pub-id-type='pmid'>12086681</pub-id></mixed-citation></ref><ref id='B49'><mixed-citation publication-type='journal'><name><surname>Sayre</surname><given-names>LM</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Schubert</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><article-title>In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals</article-title><source>J Neurochem</source><year>2000</year><volume>74</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type='pmid'>10617129</pub-id></mixed-citation></ref><ref id='B50'><mixed-citation publication-type='journal'><name><surname>Juurlink</surname><given-names>BH</given-names></name><name><surname>Paterson</surname><given-names>PG</given-names></name><article-title>Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies</article-title><source>J Spinal Cord Med</source><year>1998</year><volume>21</volume><fpage>309</fpage><lpage>334</lpage><pub-id pub-id-type='pmid'>10096045</pub-id></mixed-citation></ref><ref id='B51'><mixed-citation publication-type='journal'><name><surname>Anandatheerthavarada</surname><given-names>HK</given-names></name><name><surname>Biswas</surname><given-names>G</given-names></name><name><surname>Robin</surname><given-names>MA</given-names></name><name><surname>Avadhani</surname><given-names>NG</given-names></name><article-title>Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells</article-title><source>J Cell Biol</source><year>2003</year><volume>161</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type='doi'>10.1083/jcb.200207030</pub-id><pub-id pub-id-type='pmid'>12695498</pub-id></mixed-citation></ref><ref id='B52'><mixed-citation publication-type='journal'><name><surname>LaFerla</surname><given-names>FM</given-names></name><name><surname>Green</surname><given-names>KN</given-names></name><name><surname>Oddo</surname><given-names>S</given-names></name><article-title>Intracellular amyloid-β in Alzheimer's disease</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type='doi'>10.1038/nrn2168</pub-id><pub-id pub-id-type='pmid'>17551515</pub-id></mixed-citation></ref><ref id='B53'><mixed-citation publication-type='journal'><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><article-title>Alzheimer's APP mangles mitochondria</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>1241</fpage><lpage>1243</lpage><pub-id pub-id-type='doi'>10.1038/nm1106-1241</pub-id><pub-id pub-id-type='pmid'>17088888</pub-id></mixed-citation></ref><ref id='B54'><mixed-citation publication-type='journal'><name><surname>Takuma</surname><given-names>K</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Fukuzaki</surname><given-names>E</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Sosunov</surname><given-names>A</given-names></name><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Funatsu</surname><given-names>Y</given-names></name><name><surname>Nakamichi</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Mizoguchi</surname><given-names>H</given-names></name><name><surname>Ibi</surname><given-names>D</given-names></name><name><surname>Hori</surname><given-names>O</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>SS</given-names></name><article-title>RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>20021</fpage><lpage>20026</lpage><pub-id pub-id-type='pmid'>19901339</pub-id></mixed-citation></ref><ref id='B55'><mixed-citation publication-type='journal'><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><article-title>RAGE: A potential target for Aβ-mediated cellular perturbation in Alzheimer's disease</article-title><source>Curr Mol Med</source><year>2007</year><volume>7</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type='doi'>10.2174/156652407783220741</pub-id><pub-id pub-id-type='pmid'>18331231</pub-id></mixed-citation></ref><ref id='B56'><mixed-citation publication-type='journal'><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Keller</surname><given-names>JN</given-names></name><article-title>Evaluation of rage isoforms, ligands, and signaling in the brain</article-title><source>Biochim Biophys Acta</source><year>2005</year><volume>1746</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type='doi'>10.1016/j.bbamcr.2005.08.006</pub-id><pub-id pub-id-type='pmid'>16214242</pub-id></mixed-citation></ref><ref id='B57'><mixed-citation publication-type='journal'><name><surname>Origlia</surname><given-names>N</given-names></name><name><surname>Righi</surname><given-names>M</given-names></name><name><surname>Capsoni</surname><given-names>S</given-names></name><name><surname>Cattaneo</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Stern</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Domenici</surname><given-names>L</given-names></name><article-title>Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>3521</fpage><lpage>3530</lpage><pub-id pub-id-type='doi'>10.1523/JNEUROSCI.0204-08.2008</pub-id><pub-id pub-id-type='pmid'>18367618</pub-id></mixed-citation></ref><ref id='B58'><mixed-citation publication-type='journal'><name><surname>Origlia</surname><given-names>N</given-names></name><name><surname>Capsoni</surname><given-names>S</given-names></name><name><surname>Cattaneo</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Domenici</surname><given-names>L</given-names></name><article-title>Aβ-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: The role of RAGE</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>17</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type='pmid'>19221410</pub-id></mixed-citation></ref><ref id='B59'><mixed-citation publication-type='journal'><name><surname>Onyango</surname><given-names>IG</given-names></name><name><surname>Tuttle</surname><given-names>JB</given-names></name><name><surname>Bennett</surname><given-names>JP</given-names><suffix>Jr</suffix></name><article-title>Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE)</article-title><source>Mol Cell Neurosci</source><year>2005</year><volume>29</volume><fpage>333</fpage><lpage>343</lpage><pub-id pub-id-type='doi'>10.1016/j.mcn.2005.02.012</pub-id><pub-id pub-id-type='pmid'>15911356</pub-id></mixed-citation></ref><ref id='B60'><mixed-citation publication-type='journal'><name><surname>Habtemariam</surname><given-names>S</given-names></name><article-title>Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor in L-929 tumor cells</article-title><source>J Nat Prod</source><year>1997</year><volume>60</volume><fpage>775</fpage><lpage>778</lpage><pub-id pub-id-type='doi'>10.1021/np960581z</pub-id><pub-id pub-id-type='pmid'>9287415</pub-id></mixed-citation></ref><ref id='B61'><mixed-citation publication-type='journal'><name><surname>Sala</surname><given-names>A</given-names></name><name><surname>Recio</surname><given-names>MC</given-names></name><name><surname>Schinella</surname><given-names>GR</given-names></name><name><surname>Máñez</surname><given-names>S</given-names></name><name><surname>Giner</surname><given-names>RM</given-names></name><name><surname>Cerdá-Nicolás</surname><given-names>M</given-names></name><name><surname>Rosí</surname><given-names>JL</given-names></name><article-title>Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside</article-title><source>Eur J Pharmacol</source><year>2003</year><volume>461</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type='doi'>10.1016/S0014-2999(02)02953-9</pub-id><pub-id pub-id-type='pmid'>12568916</pub-id></mixed-citation></ref><ref id='B62'><mixed-citation publication-type='journal'><name><surname>Christophe</surname><given-names>M</given-names></name><name><surname>Nicolas</surname><given-names>S</given-names></name><article-title>Mitochondria: a target for neuroprotective interventions in cerebral ischemia-reperfusion</article-title><source>Curr Pharm Des</source><year>2006</year><volume>12</volume><fpage>739</fpage><lpage>757</lpage><pub-id pub-id-type='doi'>10.2174/138161206775474242</pub-id><pub-id pub-id-type='pmid'>16472163</pub-id></mixed-citation></ref><ref id='B63'><mixed-citation publication-type='journal'><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name><article-title>Mammalian MAP kinase signalling cascades</article-title><source>Nature</source><year>2001</year><volume>410</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type='doi'>10.1038/35065000</pub-id><pub-id pub-id-type='pmid'>11242034</pub-id></mixed-citation></ref><ref id='B64'><mixed-citation publication-type='journal'><name><surname>Lao</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>DC</given-names></name><article-title>Study of the functional role of Bcl-2 family proteins in regulating Ca(2+) signals in apoptotic cells</article-title><source>Biochem Soc Trans</source><year>2007</year><volume>35</volume><fpage>1038</fpage><lpage>1039</lpage><pub-id pub-id-type='doi'>10.1042/BST0351038</pub-id><pub-id pub-id-type='pmid'>17956272</pub-id></mixed-citation></ref><ref id='B65'><mixed-citation publication-type='journal'><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Nijhawan</surname><given-names>D</given-names></name><name><surname>Budihardjo</surname><given-names>I</given-names></name><name><surname>Srinivasula</surname><given-names>SM</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Alnemri</surname><given-names>ES</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><article-title>Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade</article-title><source>Cell</source><year>1997</year><volume>91</volume><fpage>479</fpage><lpage>489</lpage><pub-id pub-id-type='doi'>10.1016/S0092-8674(00)80434-1</pub-id><pub-id pub-id-type='pmid'>9390557</pub-id></mixed-citation></ref><ref id='B66'><mixed-citation publication-type='journal'><name><surname>Eminel</surname><given-names>S</given-names></name><name><surname>Klettner</surname><given-names>A</given-names></name><name><surname>Roemer</surname><given-names>L</given-names></name><name><surname>Herdegen</surname><given-names>T</given-names></name><name><surname>Waetzig</surname><given-names>V</given-names></name><article-title>JNK2 translocates to the mitochondria and mediates cytochrome c release in PC 12 cells in response to 6-hydroxydopamine</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>55385</fpage><lpage>55392</lpage><pub-id pub-id-type='doi'>10.1074/jbc.M405858200</pub-id><pub-id pub-id-type='pmid'>15504737</pub-id></mixed-citation></ref><ref id='B67'><mixed-citation publication-type='journal'><name><surname>Tournier</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>DD</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>TK</given-names></name><name><surname>Nimnual</surname><given-names>A</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name><article-title>Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway</article-title><source>Science</source><year>2000</year><volume>288</volume><fpage>870</fpage><lpage>874</lpage><pub-id pub-id-type='doi'>10.1126/science.288.5467.870</pub-id><pub-id pub-id-type='pmid'>10797012</pub-id></mixed-citation></ref><ref id='B68'><mixed-citation publication-type='journal'><name><surname>King</surname><given-names>M</given-names></name><name><surname>Nafar</surname><given-names>F</given-names></name><name><surname>Clarke</surname><given-names>J</given-names></name><name><surname>Mearow</surname><given-names>K</given-names></name><article-title>The small heat shock protein Hsp27 protects cortical neurons against the toxic effects of beta-amyloid peptide</article-title><source>J Neurosci Res</source><year>2009</year><volume>87</volume><fpage>3161</fpage><lpage>3175</lpage><pub-id pub-id-type='doi'>10.1002/jnr.22145</pub-id><pub-id pub-id-type='pmid'>19530165</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>